

Table 1.22  
U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2014<sup>a</sup>  
Using Different Tumor Inclusion Criteria<sup>b</sup>

Site	Sex	5-Year Limited Duration			39-year Limited Duration	
		1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 39 Years <sup>d</sup>	1st Per Site in Previous 5 Years <sup>e</sup>	1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 39 Years <sup>d</sup>
All Sites	Both Sexes	4,707,603	4,804,644	5,327,036	14,176,073	14,407,725
	Male	2,358,463	2,396,232	2,650,453	6,724,873	6,805,012
	Female	2,349,140	2,408,412	2,676,583	7,451,200	7,602,713
Oral Cavity & Pharynx	Both Sexes	115,978	135,161	140,597	304,660	338,216
	Male	81,880	94,793	97,971	204,620	225,419
	Female	34,098	40,368	42,626	100,040	112,797
Esophagus	Both Sexes	22,547	27,932	28,052	38,340	45,433
	Male	17,820	21,866	21,937	30,067	35,402
	Female	4,727	6,066	6,115	8,273	10,031
Stomach	Both Sexes	40,042	48,260	48,945	81,801	94,587
	Male	23,682	28,847	29,232	46,828	54,495
	Female	16,360	19,413	19,713	34,973	40,092
Colon & Rectum	Both Sexes	387,571	446,369	455,675	1,169,200	1,300,518
	Male	199,704	229,611	234,110	585,071	648,151
	Female	187,867	216,758	221,565	584,129	652,367
Liver & Intrahepatic Bile Duct	Both Sexes	40,871	47,284	47,447	58,508	66,223
	Male	30,107	34,345	34,461	41,859	46,823
	Female	10,764	12,939	12,986	16,649	19,400
Pancreas	Both Sexes	39,896	48,921	48,944	53,505	64,361
	Male	20,062	24,740	24,763	26,229	31,846
	Female	19,834	24,181	24,181	27,276	32,515
Larynx	Both Sexes	31,963	37,495	38,022	87,985	98,733
	Male	25,808	30,349	30,784	70,747	79,284
	Female	6,155	7,146	7,238	17,238	19,449
Lung & Bronchus	Both Sexes	238,175	309,108	320,324	417,234	520,195
	Male	107,162	141,514	145,870	183,435	230,476
	Female	131,013	167,594	174,454	233,799	289,719
Melanoma of the Skin	Both Sexes	299,475	343,659	362,526	1,045,262	1,134,384
	Male	162,271	191,131	203,296	521,277	574,367
	Female	137,204	152,528	159,230	523,985	560,017
Breast	Female	906,033	984,111	1,048,649	3,097,860	3,287,692
Cervix	Female	38,533	40,724	40,793	218,501	224,665
Corpus & Uterus, NOS	Female	195,484	219,407	219,611	631,801	691,628
Ovary <sup>f</sup>	Female	61,143	70,057	70,127	184,919	207,305

<sup>a</sup> U.S. 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER 9 registries and 1/1/2014 U.S. population estimates based on the average of 2013 and 2014 population estimates from the U.S. Bureau of the Census.

<sup>b</sup> Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

<sup>c</sup> (c) First invasive tumor ever

<sup>d</sup> (d) First invasive tumor for each cancer site diagnosed during the previous 39 years (1975-2013)

<sup>e</sup> (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2009-2013)  
For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2009; Melanoma in 2010.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 39-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2014.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 39-year limited duration prevalence. The 2009 breast cancer is counted for the breast 5-year and 39-year limited duration prevalence.

In method (e) the 2009 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2010 melanoma is counted for 5-year limited duration prevalence for melanoma.

<sup>f</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.22 - continued  
 U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2014<sup>a</sup>  
 Using Different Tumor Inclusion Criteria<sup>b</sup>

Site	Sex	5-Year Limited Duration			39-year Limited Duration	
		1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 39 Years <sup>d</sup>	1st Per Site in Previous 5 Years <sup>e</sup>	1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 39 Years <sup>d</sup>
Prostate	Male	958,284	1,038,106	1,038,153	2,896,908	3,084,494
Testis	Male	43,188	44,173	44,790	233,387	236,737
Urinary Bladder	Both Sexes	204,650	258,837	264,918	584,564	686,874
	Male	156,415	198,781	203,732	437,376	514,987
	Female	48,235	60,056	61,186	147,188	171,887
Kidney & Renal Pelvis	Both Sexes	161,395	197,797	200,804	403,200	471,919
	Male	101,224	125,184	127,262	241,820	285,673
	Female	60,171	72,613	73,542	161,380	186,246
Brain & Nervous System	Both Sexes	46,934	50,188	50,674	144,554	149,412
	Male	25,809	27,507	27,751	76,849	79,285
	Female	21,125	22,681	22,923	67,705	70,127
Thyroid	Both Sexes	202,213	226,966	227,711	637,312	686,320
	Male	45,343	53,812	53,948	137,898	152,992
	Female	156,870	173,154	173,763	499,414	533,328
Hodgkin Lymphoma	Both Sexes	36,864	39,181	39,262	185,935	191,423
	Male	20,013	21,282	21,338	96,384	99,217
	Female	16,851	17,899	17,924	89,551	92,206
Non-Hodgkin Lymphoma	Both Sexes	209,107	247,513	252,349	581,742	653,653
	Male	112,529	134,140	136,678	307,368	346,181
	Female	96,578	113,373	115,671	274,374	307,472
Myeloma	Both Sexes	64,023	75,648	76,097	102,617	118,273
	Male	34,735	42,231	42,518	55,465	65,186
	Female	29,288	33,417	33,579	47,152	53,087
Leukemia	Both Sexes	128,087	151,081	151,699	343,991	381,774
	Male	74,309	88,049	88,376	195,093	217,430
	Female	53,778	63,032	63,323	148,898	164,344
Acute Lymphocytic Leukemia	Both Sexes	17,262	17,937	17,937	77,350	78,272
	Male	9,297	9,674	9,674	42,200	42,660
	Female	7,965	8,263	8,263	35,150	35,612
Childhood (Ages 0-19)	Both Sexes	66,888	67,020	67,615	348,190	348,772
	Male	34,669	34,757	35,067	178,759	179,034
	Female	32,219	32,263	32,548	169,431	169,738
Kaposi Sarcoma	Both Sexes	7,115	7,712	7,712	27,719	29,174
	Male	6,562	7,119	7,119	26,210	27,519
	Female	553	593	593	1,509	1,655
Mesothelioma	Both Sexes	3,155	4,083	4,083	4,860	5,905
	Male	2,157	2,873	2,873	2,855	3,628
	Female	998	1,210	1,210	2,005	2,277

<sup>a</sup> U.S. 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER 9 registries and 1/1/2014 U.S. population estimates based on the average of 2013 and 2014 population estimates from the U.S. Bureau of the Census.

<sup>b</sup> Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

<sup>c</sup> (c) First invasive tumor ever  
<sup>d</sup> (d) First invasive tumor for each cancer site diagnosed during the previous 39 years (1975-2013)  
<sup>e</sup> (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2009-2013)  
 For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2009; Melanoma in 2010.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 39-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2014. In method (d) the 1981 melanoma is counted for the melanoma and all sites 39-year limited duration prevalence. The 2009 breast cancer is counted for the breast 5-year and 39-year limited duration prevalence. In method (e) the 2009 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2010 melanoma is counted for 5-year limited duration prevalence for melanoma.

Table 1.23  
U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2014<sup>a</sup>  
By Age at Prevalence

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Site/Sex	Age at Prevalence								
	All Ages <sup>c</sup>	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
All Sites									
Males	6,872,623	18,786	43,295	91,310	166,204	350,387	937,944	1,835,673	3,429,024
Females	7,866,096	17,222	37,437	93,801	242,346	639,430	1,424,917	1,995,951	3,414,992
Oral Cavity & Pharynx									
Males	230,233	45	454	1,771	3,759	13,831	51,146	76,136	83,090
Females	116,669	107	542	1,594	4,163	8,877	21,084	30,278	50,024
Esophagus									
Males	35,460	0	0	29	181	1,003	5,067	12,194	16,986
Females	10,087	0	0	0	44	190	1,441	2,846	5,566
Stomach									
Males	55,180	0	11	168	589	2,749	8,310	14,682	28,670
Females	40,584	0	44	210	842	2,454	5,947	9,160	21,926
Colon & Rectum									
Males	653,863	22	146	1,263	6,349	26,922	91,558	156,306	371,297
Females	663,384	0	261	1,482	6,650	24,542	80,676	130,589	419,183
Liver & Intrahep									
Males	46,895	611	536	603	632	1,608	11,275	19,864	11,766
Females	19,876	418	591	486	471	1,059	3,816	6,321	6,715
Pancreas									
Males	31,986	23	35	117	493	1,812	5,719	9,976	13,812
Females	32,682	0	23	347	628	1,721	5,972	8,601	15,389
Larynx									
Males	80,249	0	0	80	285	1,810	10,178	23,304	44,592
Females	19,665	0	0	17	142	859	3,485	5,914	9,247
Lung & Bronchus									
Males	234,540	34	98	470	1,266	5,330	26,088	64,649	136,605
Females	292,688	56	92	401	1,684	6,863	35,794	75,197	172,603
Melanoma of the Skin									
Males	585,672	67	706	4,931	18,016	45,764	104,327	160,068	251,795
Females	583,679	107	813	10,439	36,175	74,208	129,434	142,681	189,821

<sup>a</sup> U.S. 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2014 U.S. population estimates based on the average of 2013 and 2014 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39 years (1975-2013).

<sup>b</sup> Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

<sup>c</sup> Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table 1.23 - continued  
 U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2014<sup>a</sup>  
 By Age at Prevalence

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
 Please see the Prevalence Comparison Chapter of this CSR for more information.

Site/Sex	Age at Prevalence								
	All Ages <sup>c</sup>	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
Breast									
Males	18,835	0	0	11	76	672	2,123	5,001	10,951
Females	3,327,552	11	47	3,031	38,197	215,565	597,561	910,098	1,563,042
Cervix									
Females	256,078	0	81	2,075	14,495	40,908	60,284	61,931	76,305
Corpus & Uterus, NOS									
Females	710,228	11	35	727	6,574	27,036	100,667	205,938	369,240
Ovary <sup>d</sup>									
Females	222,060	81	1,038	3,954	7,233	18,751	46,165	61,136	83,701
Prostate									
Males	3,085,209	45	47	79	338	17,434	240,617	859,940	1,966,708
Urinary Bladder									
Males	521,201	68	117	524	2,521	9,466	44,105	118,578	345,823
Females	175,239	79	34	246	972	3,819	14,892	36,157	119,040
Kidney & Renal Pelvis									
Males	292,058	1,399	2,329	3,006	5,751	20,940	52,404	82,949	123,279
Females	191,167	1,616	2,455	3,238	5,310	13,603	33,033	47,535	84,377
Hodgkin Lymphoma									
Males	105,489	209	2,301	9,666	16,550	23,334	24,766	18,035	10,629
Females	98,576	45	2,147	9,466	16,634	22,567	23,051	14,306	10,361
Non-Hodgkin Lymphoma									
Males	350,647	831	4,019	8,336	14,494	30,378	61,177	88,332	143,081
Females	311,349	547	1,536	4,919	9,944	21,497	48,615	75,964	148,327
Myeloma									
Males	65,283	0	18	87	605	3,537	10,446	19,742	30,849
Females	53,256	0	0	69	480	2,374	8,379	15,856	26,099
Leukemia									
Males	219,989	6,599	13,513	14,405	12,981	16,403	29,092	46,712	80,285
Females	167,739	5,984	10,654	12,441	11,619	12,517	20,169	30,950	63,404
Acute Lymphocytic Leuk									
Males	44,485	5,568	11,217	11,145	7,420	5,011	2,295	1,096	732
Females	37,352	5,088	9,067	8,947	6,522	3,972	1,798	1,285	672

<sup>a</sup> U.S. 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2014 U.S. population estimates based on the average of 2013 and 2014 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39 years (1975-2013).

<sup>b</sup> Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

<sup>c</sup> Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table 2.21  
All Cancer Sites (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	4,811,335	3,458,926	2,487,009	1,607,842	979,134	572,214	13,168,343	14,407,575	331,144	14,738,719
	Males	2,398,374	1,760,830	1,211,624	716,170	389,057	183,754	6,416,572	6,804,930	67,693	6,872,623
	Females	2,412,961	1,698,096	1,275,385	891,672	590,077	388,460	6,751,771	7,602,645	263,451	7,866,096
White <sup>b</sup>	Both Sexes	4,023,367	2,962,254	2,170,661	1,417,248	879,656	518,734	11,293,349	12,418,373	288,481	12,706,854
	Males	2,002,155	1,500,367	1,051,300	628,853	352,400	168,856	5,480,191	5,837,863	63,500	5,901,363
	Females	2,021,212	1,461,887	1,119,361	788,395	527,256	349,878	5,813,158	6,580,510	224,981	6,805,491
Black <sup>b</sup>	Both Sexes	512,252	326,396	212,690	125,208	63,844	33,107	1,230,198	1,301,463	20,638	1,322,101
	Males	265,247	178,106	114,764	61,405	24,687	8,967	641,281	659,527	1,614	661,141
	Females	247,005	148,290	97,926	63,803	39,157	24,140	588,917	641,936	19,024	660,960
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	163,354	104,909	68,579	41,293	+	+	387,801	+	+	+
	Males	66,872	43,218	26,311	14,086	+	+	153,629	+	+	+
	Females	96,482	61,691	42,268	27,207	+	+	234,172	+	+	+
Hispanic <sup>d</sup>	Both Sexes	360,571	234,592	153,660	93,427	+	+	865,806	+	+	+
	Males	164,021	109,492	68,272	38,406	+	+	389,118	+	+	+
	Females	196,550	125,100	85,388	55,021	+	+	476,688	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)					Age-Adjusted <sup>f</sup>	
						30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	3.6726%	0.0859%	0.1918%	0.3568%	0.8240%	2.0056%	4.6050%	9.8334%	17.1858%	20.0608%	3.4366%
	Males	3.5781%	0.0885%	0.2024%	0.3478%	0.6534%	1.3766%	3.6863%	10.1455%	21.1175%	27.7173%	3.7334%
	Females	3.7649%	0.0832%	0.1808%	0.3662%	0.9961%	2.6288%	5.4871%	9.5517%	13.9675%	15.4474%	3.2830%
White <sup>c</sup>	Both Sexes	4.0665%	0.0929%	0.2108%	0.4063%	0.9283%	2.1632%	4.8293%	10.2825%	18.1910%	21.1239%	3.6387%
	Males	3.9322%	0.0947%	0.2229%	0.3990%	0.7455%	1.5103%	3.8325%	10.4111%	21.9237%	28.6276%	3.8915%
	Females	4.2003%	0.0910%	0.1981%	0.4142%	1.1209%	2.8389%	5.8188%	10.1621%	15.0517%	16.5393%	3.5245%
Black <sup>c</sup>	Both Sexes	2.7570%	0.0667%	0.1364%	0.2260%	0.5605%	1.6357%	4.3487%	10.2399%	17.0707%	17.5782%	3.2346%
	Males	2.9887%	0.0698%	0.1395%	0.2172%	0.4110%	1.1550%	4.1546%	12.8883%	24.8996%	29.2823%	4.1795%
	Females	2.5457%	0.0635%	0.1332%	0.2346%	0.6924%	2.0569%	4.5183%	8.1676%	11.6193%	11.7790%	2.6610%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	2.3212%	0.0657%	0.1414%	0.2206%	0.5032%	1.4265%	3.2873%	6.2783%	10.3231%	13.4483%	2.2360%
	Males	1.9548%	0.0706%	0.1490%	0.2038%	0.3371%	0.7341%	2.0281%	5.3728%	11.6467%	18.1039%	2.1377%
	Females	2.6577%	0.0606%	0.1335%	0.2377%	0.6543%	2.0388%	4.3723%	7.0195%	9.2902%	10.5876%	2.3681%
Hispanic <sup>d</sup>	Both Sexes	1.6302%	0.0792%	0.1831%	0.2931%	0.6247%	1.4179%	3.2774%	6.9661%	12.2766%	14.5657%	2.4873%
	Males	1.4427%	0.0820%	0.1948%	0.2973%	0.4845%	0.8960%	2.3041%	6.7216%	15.4395%	21.0468%	2.6791%
	Females	1.8206%	0.0762%	0.1711%	0.2884%	0.7740%	1.9601%	4.2201%	7.1779%	9.9162%	10.6486%	2.4322%

- <sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry  
<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
<sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.  
<sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.  
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.  
+ Not available.

Table 3.21  
Brain and Other Nervous System (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases. Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	50,188	27,999	22,818	16,569	13,466	9,347	128,802	149,421	12,920	162,341
	Males	27,507	14,793	11,194	8,909	7,490	4,820	68,648	79,296	5,915	85,211
	Females	22,681	13,206	11,624	7,660	5,976	4,527	60,154	70,125	7,005	77,130
White <sup>b</sup>	Both Sexes	43,050	24,249	19,988	14,357	11,872	8,355	111,527	129,975	2,479	132,454
	Males	23,739	12,908	9,947	7,765	6,546	4,234	59,774	69,303	1,569 <sup>i</sup>	70,872
	Females	19,311	11,341	10,041	6,592	5,326	4,121	51,753	60,672	910 <sup>i</sup>	61,582
Black <sup>b</sup>	Both Sexes	4,309	2,296	1,796	1,360	1,083	676	10,643	12,234	+	+
	Males	2,245	1,080	799	704	626	399	5,366	6,167	+	+
	Females	2,064	1,216	997	656	457	277	5,277	6,067	+	+
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	1,635	881	653	460	+	+	3,777	+	+	+
	Males	842	444	305	198	+	+	1,888	+	+	+
	Females	793	437	348	262	+	+	1,889	+	+	+
Hispanic <sup>d</sup>	Both Sexes	5,319	3,241	2,588	1,675	+	+	13,336	+	+	+
	Males	2,828	1,775	1,315	854	+	+	7,002	+	+	+
	Females	2,491	1,466	1,273	821	+	+	6,334	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)					Age-Adjusted <sup>f</sup>	
						30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.0353%	0.0144%	0.0340%	0.0365%	0.0357%	0.0394%	0.0456%	0.0448%	0.0391%	0.0233%	0.0347%
	Males	0.0382%	0.0147%	0.0352%	0.0383%	0.0381%	0.0438%	0.0495%	0.0506%	0.0455%	0.0276%	0.0375%
	Females	0.0326%	0.0141%	0.0327%	0.0346%	0.0332%	0.0351%	0.0419%	0.0396%	0.0339%	0.0206%	0.0320%
White <sup>c</sup>	Both Sexes	0.0403%	0.0161%	0.0378%	0.0421%	0.0412%	0.0456%	0.0525%	0.0498%	0.0434%	0.0248%	0.0394%
	Males	0.0435%	0.0163%	0.0392%	0.0442%	0.0433%	0.0506%	0.0566%	0.0555%	0.0509%	0.0299%	0.0425%
	Females	0.0371%	0.0158%	0.0363%	0.0399%	0.0390%	0.0405%	0.0484%	0.0446%	0.0371%	0.0216%	0.0364%
Black <sup>c</sup>	Both Sexes	0.0230%	0.0110%	0.0254%	0.0240%	0.0249%	0.0244%	0.0241%	0.0313%	0.0249%	0.0180%	0.0229%
	Males	0.0239%	0.0111%	0.0262%	0.0253%	0.0245%	0.0261%	0.0249%	0.0347%	0.0310%	0.0143%	0.0240%
	Females	0.0222%	0.0110%	0.0245%	0.0228%	0.0253%	0.0228%	0.0233%	0.0287%	0.0207%	0.0198%	0.0219%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0198%	0.0086%	0.0216%	0.0200%	0.0181%	0.0207%	0.0248%	0.0250%	0.0248%	0.0161%	0.0196%
	Males	0.0207%	0.0091%	0.0212%	0.0199%	0.0209%	0.0216%	0.0252%	0.0296%	0.0236%	0.0185%	0.0205%
	Females	0.0190%	0.0080%	0.0221%	0.0201%	0.0155%	0.0199%	0.0245%	0.0212%	0.0258%	0.0146%	0.0188%
Hispanic <sup>d</sup>	Both Sexes	0.0246%	0.0109%	0.0256%	0.0228%	0.0231%	0.0294%	0.0393%	0.0338%	0.0325%	0.0270%	0.0259%
	Males	0.0255%	0.0115%	0.0268%	0.0219%	0.0220%	0.0331%	0.0422%	0.0377%	0.0358%	0.0309%	0.0274%
	Females	0.0237%	0.0104%	0.0244%	0.0237%	0.0242%	0.0255%	0.0366%	0.0303%	0.0300%	0.0246%	0.0246%

<sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry  
<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
<sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.  
<sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.  
<sup>-</sup> Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.  
<sup>+</sup> Not available.

Table 4.24  
Cancer of the Breast (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	992,786	749,029	604,511	420,086	265,340	158,399	2,985,647	3,306,425	39,962	3,346,387
	Males	8,065	4,445	2,975	1,591	771	502	17,763	18,729	106	18,835
	Females	984,721	744,584	601,536	418,495	264,569	157,897	2,967,884	3,287,696	39,856	3,327,552
White <sup>b</sup>	Both Sexes	829,791	643,093	531,954	372,775	237,980	143,539	2,573,918	2,864,694	35,145	2,899,839
	Males	6,559	3,898	2,422	1,447	676	433	14,931	15,791	0 <sup>i</sup>	15,791
	Females	823,232	639,195	529,532	371,328	237,304	143,106	2,558,987	2,848,903	35,145	2,884,048
Black <sup>b</sup>	Both Sexes	106,559	68,983	47,290	31,019	18,227	10,061	269,070	289,503	+	+
	Males	1,248	423	450	80	73	59	2,262	2,358	+	+
	Females	105,311	68,560	46,840	30,939	18,154	10,002	266,808	287,145	3,155	290,300
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	42,168	28,907	20,281	12,642	+	+	107,031	+	+	+
	Males	167	83	60	32	+	+	364	+	+	+
	Females	42,001	28,824	20,221	12,610	+	+	106,667	+	+	+
Hispanic <sup>d</sup>	Both Sexes	73,458	49,975	34,478	21,507	+	+	184,655	+	+	+
	Males	368	194	107	53	+	+	729	+	+	+
	Females	73,090	49,781	34,371	21,454	+	+	183,926	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)					Age-Adjusted <sup>f</sup>	
						30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.8383%	-	0.0001%	0.0068%	0.0888%	0.4916%	1.2849%	2.4279%	3.6738%	4.3313%	0.7694%
	Males	0.0097%	-	-	-	0.0004%	0.0028%	0.0093%	0.0277%	0.0621%	0.0914%	0.0103%
	Females	1.6462%	-	0.0002%	0.0138%	0.1780%	0.9758%	2.5094%	4.5955%	6.6302%	6.8860%	1.4108%
White <sup>c</sup>	Both Sexes	0.9225%	-	0.0002%	0.0064%	0.0872%	0.4928%	1.3164%	2.5419%	3.9405%	4.6619%	0.8073%
	Males	0.0106%	-	-	-	0.0003%	0.0027%	0.0085%	0.0282%	0.0663%	0.0970%	0.0107%
	Females	1.8313%	-	0.0003%	0.0131%	0.1788%	1.0001%	2.6147%	4.8947%	7.1986%	7.4509%	1.4995%
Black <sup>c</sup>	Both Sexes	0.6111%	-	-	0.0077%	0.1014%	0.4950%	1.2072%	2.2223%	3.2020%	3.6165%	0.6997%
	Males	0.0100%	-	-	-	-	0.0053%	0.0185%	0.0399%	0.0755%	0.1023%	0.0139%
	Females	1.1591%	-	-	0.0153%	0.1901%	0.9240%	2.2462%	3.9300%	5.3791%	5.3578%	1.2064%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.6354%	-	-	0.0077%	0.0865%	0.4888%	1.1880%	1.9307%	2.4704%	2.7376%	0.5983%
	Males	0.0047%	-	-	-	-	-	0.0052%	0.0147%	0.0276%	0.0465%	0.0052%
	Females	1.2146%	-	-	0.0155%	0.1647%	0.9200%	2.2072%	3.4993%	4.3764%	4.3912%	1.0722%
Hispanic <sup>d</sup>	Both Sexes	0.3509%	-	-	0.0051%	0.0678%	0.3410%	0.9281%	1.7423%	2.4882%	2.7379%	0.5338%
	Males	0.0027%	-	-	-	-	0.0017%	0.0037%	0.0151%	0.0295%	0.0539%	0.0055%
	Females	0.7048%	-	-	0.0105%	0.1395%	0.6936%	1.8235%	3.2388%	4.3231%	4.3602%	0.9712%

- <sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry  
<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
<sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.  
<sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.  
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.  
+ Not available.

Table 5.15  
Cancer of the Cervix Uteri (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases. Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>e</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>										
All Races <sup>b</sup>	40,724	33,106	33,195	34,217	30,181	23,412	165,629	224,653	31,425	256,078
White <sup>b</sup>	32,013	26,245	26,641	27,640	25,285	19,747	132,854	182,214	26,722	208,936
Black <sup>b</sup>	5,351	4,534	4,318	3,992	3,111	2,436	20,797	27,621	+	+
Asian/Pacific Islander <sup>c</sup>	2,262	1,769	1,659	1,690	+	+	7,874	+	+	+
Hispanic <sup>d</sup>	7,863	7,135	7,284	5,979	+	+	30,362	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence and Race/Ethnicity

Age at Prevalence	All Ages	Age Specific (Crude)									Age-Adjusted <sup>f</sup>	
		0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages	
<u>Race</u>												
All Races <sup>c</sup>	0.1023%	-	0.0003%	0.0085%	0.0670%	0.1878%	0.2199%	0.2049%	0.1786%	0.1237%	0.0946%	
White <sup>c</sup>	0.1073%	-	0.0003%	0.0097%	0.0773%	0.2103%	0.2309%	0.1990%	0.1632%	0.1043%	0.0991%	
Black <sup>c</sup>	0.0861%	-	-	0.0056%	0.0522%	0.1518%	0.1891%	0.2182%	0.2117%	0.1722%	0.0872%	
Asian/Pacific Islander <sup>c</sup>	0.0869%	-	-	0.0047%	0.0288%	0.1051%	0.1757%	0.2171%	0.2381%	0.2093%	0.0776%	
Hispanic <sup>d</sup>	0.1159%	-	-	0.0090%	0.0775%	0.2222%	0.3461%	0.3725%	0.3607%	0.2815%	0.1438%	

<sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census. Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years.

<sup>b c d</sup> Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry

(d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.

<sup>e</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.

<sup>f</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

<sup>g h i</sup> (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.



Table 6.28  
Cancer of the Colon and Rectum (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	446,441	319,009	228,355	137,927	83,797	48,939	1,201,178	1,300,487	16,760	1,317,247
	Males	229,635	159,865	114,830	67,339	40,339	22,114	605,736	648,116	5,747	653,863
	Females	216,806	159,144	113,525	70,588	43,458	26,825	595,442	652,371	11,013	663,384
White <sup>b</sup>	Both Sexes	363,299	267,148	194,848	118,139	72,840	42,989	1,003,907	1,091,218	14,709	1,105,927
	Males	187,417	135,938	99,119	57,994	35,512	19,784	510,501	548,326	5,095	553,421
	Females	175,882	131,210	95,729	60,145	37,328	23,205	493,406	542,892	9,614	552,506
Black <sup>b</sup>	Both Sexes	53,349	33,575	22,080	13,237	7,330	4,103	128,116	136,362	1,259	137,621
	Males	26,365	14,630	9,824	5,882	3,149	1,404	59,294	62,057	414	62,471
	Females	26,984	18,945	12,256	7,355	4,181	2,699	68,822	74,305	845	75,150
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	20,589	13,269	8,423	5,055	+	+	48,554	+	+	+
	Males	10,854	6,775	4,172	2,526	+	+	24,902	+	+	+
	Females	9,735	6,494	4,251	2,529	+	+	23,652	+	+	+
Hispanic <sup>d</sup>	Both Sexes	35,578	21,761	12,252	7,109	+	+	78,442	+	+	+
	Males	18,706	11,410	6,149	3,637	+	+	40,763	+	+	+
	Females	16,872	10,351	6,103	3,472	+	+	37,679	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)									Age-Adjusted <sup>f</sup>	
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.3403%	-	0.0008%	0.0054%	0.0284%	0.1147%	0.3768%	0.8154%	1.6896%	2.8467%	0.3182%
	Males	0.3482%	-	0.0006%	0.0051%	0.0278%	0.1211%	0.4084%	0.9426%	1.9905%	3.2770%	0.3657%
	Females	0.3325%	-	0.0009%	0.0056%	0.0290%	0.1084%	0.3465%	0.7005%	1.4432%	2.5874%	0.2811%
White <sup>c</sup>	Both Sexes	0.3568%	-	0.0009%	0.0059%	0.0301%	0.1136%	0.3614%	0.7806%	1.6906%	2.9142%	0.3162%
	Males	0.3645%	-	0.0006%	0.0055%	0.0292%	0.1183%	0.3919%	0.9052%	1.9942%	3.3302%	0.3627%
	Females	0.3492%	-	0.0012%	0.0062%	0.0310%	0.1089%	0.3311%	0.6640%	1.4353%	2.6600%	0.2790%
Black <sup>c</sup>	Both Sexes	0.2896%	-	-	0.0033%	0.0238%	0.1236%	0.4400%	1.0366%	1.9164%	2.7235%	0.3530%
	Males	0.2823%	-	-	0.0032%	0.0234%	0.1323%	0.4534%	1.1619%	2.1699%	3.2933%	0.4010%
	Females	0.2962%	-	-	0.0034%	0.0241%	0.1160%	0.4283%	0.9386%	1.7399%	2.4411%	0.3221%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.3016%	-	-	0.0038%	0.0227%	0.1060%	0.3809%	0.8114%	1.4931%	2.4804%	0.2922%
	Males	0.3186%	-	-	0.0037%	0.0232%	0.1181%	0.4350%	0.9586%	1.7946%	2.9036%	0.3442%
	Females	0.2860%	-	-	0.0038%	0.0222%	0.0953%	0.3344%	0.6910%	1.2579%	2.2203%	0.2529%
Hispanic <sup>d</sup>	Both Sexes	0.1482%	-	0.0003%	0.0040%	0.0219%	0.0821%	0.2976%	0.6885%	1.3301%	2.0488%	0.2484%
	Males	0.1518%	-	-	0.0038%	0.0219%	0.0837%	0.3114%	0.8000%	1.6652%	2.5364%	0.2957%
	Females	0.1446%	-	-	0.0043%	0.0219%	0.0804%	0.2843%	0.5918%	1.0800%	1.7541%	0.2138%

- <sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry  
<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
<sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.  
<sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.  
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.  
+ Not available.

Table 7.15  
Cancer of the Corpus and Uterus, NOS (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases. Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>e</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>										
All Races <sup>b</sup>	219,407	151,168	113,801	82,189	52,013	33,968	610,358	691,630	18,598	710,228
White <sup>b</sup>	186,315	133,112	102,463	75,241	48,361	31,643	537,846	613,943	15,295	629,238
Black <sup>b</sup>	19,737	10,053	5,992	3,223	1,886	1,217	40,576	43,165	694	43,859
Asian/Pacific Islander <sup>c</sup>	9,042	5,575	3,616	2,370	+	+	21,210	+	+	+
Hispanic <sup>d</sup>	17,747	10,189	6,572	4,154	+	+	39,878	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence and Race/Ethnicity

Age at Prevalence	Age Specific (Crude)										Age-Adjusted <sup>f</sup>
	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>											
All Races <sup>c</sup>	0.3295%	-	-	0.0036%	0.0344%	0.1322%	0.4328%	1.0551%	1.4579%	1.3036%	0.2801%
White <sup>c</sup>	0.3756%	-	-	0.0032%	0.0338%	0.1325%	0.4526%	1.1444%	1.6265%	1.4741%	0.3042%
Black <sup>c</sup>	0.1747%	-	-	0.0048%	0.0250%	0.0917%	0.2462%	0.7153%	1.0455%	0.7250%	0.1849%
Asian/Pacific Islander <sup>c</sup>	0.2391%	-	-	0.0043%	0.0366%	0.1514%	0.4672%	0.8076%	0.8095%	0.6168%	0.2077%
Hispanic <sup>d</sup>	0.1527%	-	-	0.0046%	0.0459%	0.1437%	0.3651%	0.7721%	0.9563%	0.7456%	0.2086%

<sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry  
<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
<sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.  
<sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.  
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.  
+ Not available.

Table 8.21  
Cancer of the Esophagus (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	27,932	9,633	4,730	1,963	784	268	45,005	45,433	114	45,547
	Males	21,866	7,478	3,649	1,531	592	188	35,079	35,402	58	35,460
	Females	6,066	2,155	1,081	432	192	80	9,926	10,031	56	10,087
White <sup>b</sup>	Both Sexes	25,194	8,775	4,319	1,735	659	234	40,657	41,038	89	41,127
	Males	20,014	6,837	3,456	1,386	486	161	32,155	32,438	52	32,490
	Females	5,180	1,938	863	349	173	73	8,502	8,600	37	8,637
Black <sup>b</sup>	Both Sexes	1,966	592	279	170	97	26	3,092	3,130	25	3,155
	Males	1,306	448	111	98	84	26	2,035	2,073	7	2,080
	Females	660	144	168	72	13	0	1,057	1,057	18	1,075
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	507	172	86	40	+	+	825	+	+	+
	Males	354	119	50	26	+	+	566	+	+	+
Hispanic <sup>d</sup>	Both Sexes	1,280	327	130	105	+	+	1,872	+	+	+
	Males	1,020	276	109	89	+	+	1,515	+	+	+
	Females	260	51	21	16	+	+	357	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)					Age-Adjusted <sup>f</sup>	
						30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.0115%	-	-	-	0.0005%	0.0025%	0.0125%	0.0384%	0.0660%	0.0607%	0.0106%
	Males	0.0180%	-	-	-	0.0008%	0.0042%	0.0200%	0.0650%	0.1137%	0.1116%	0.0182%
	Females	0.0052%	-	-	-	0.0002%	0.0008%	0.0053%	0.0145%	0.0269%	0.0301%	0.0044%
White <sup>c</sup>	Both Sexes	0.0137%	-	-	-	0.0006%	0.0030%	0.0140%	0.0436%	0.0749%	0.0665%	0.0120%
	Males	0.0216%	-	-	-	0.0010%	0.0050%	0.0224%	0.0739%	0.1301%	0.1239%	0.0207%
	Females	0.0058%	-	-	-	-	0.0009%	0.0057%	0.0152%	0.0284%	0.0315%	0.0047%
Black <sup>c</sup>	Both Sexes	0.0066%	-	-	-	-	0.0013%	0.0104%	0.0317%	0.0443%	0.0379%	0.0077%
	Males	0.0090%	-	-	-	-	0.0019%	0.0162%	0.0478%	0.0647%	0.0665%	0.0118%
	Females	0.0044%	-	-	-	-	-	0.0052%	0.0192%	0.0301%	0.0237%	0.0048%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0051%	-	-	-	-	0.0011%	0.0066%	0.0144%	0.0296%	0.0376%	0.0050%
	Males	0.0073%	-	-	-	-	0.0015%	0.0101%	0.0234%	0.0469%	0.0576%	0.0079%
Hispanic <sup>d</sup>	Both Sexes	0.0032%	-	-	-	-	-	0.0035%	0.0071%	0.0160%	0.0253%	0.0029%
	Both Sexes	0.0035%	-	-	-	0.0006%	0.0020%	0.0070%	0.0196%	0.0321%	0.0366%	0.0058%
	Males	0.0056%	-	-	-	0.0011%	0.0033%	0.0119%	0.0337%	0.0629%	0.0680%	0.0105%
	Females	0.0014%	-	-	-	-	-	0.0022%	0.0074%	0.0091%	0.0176%	0.0020%

- <sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry  
<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
<sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.  
<sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.  
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.  
+ Not available.

Table 9.21  
Hodgkin LymphomaEstimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	39,181	37,092	29,500	26,209	22,731	18,266	150,508	191,404	12,661	204,065
	Males	21,282	19,650	15,011	13,302	11,264	8,973	78,467	99,213	6,276	105,489
	Females	17,899	17,442	14,489	12,907	11,467	9,293	72,041	92,191	6,385	98,576
White <sup>b</sup>	Both Sexes	32,465	31,096	25,477	23,275	20,628	16,903	129,008	167,254	14,017	181,271
	Males	17,813	16,489	13,064	11,866	10,226	8,207	67,556	86,656	7,318	93,974
	Females	14,652	14,607	12,413	11,409	10,402	8,696	61,452	80,598	6,699	87,297
Black <sup>b</sup>	Both Sexes	4,843	4,645	2,991	2,400	1,752	1,095	16,438	18,488	960	19,448
	Males	2,515	2,385	1,379	1,179	871	634	8,233	9,564	666	10,230
	Females	2,328	2,260	1,612	1,221	881	461	8,205	8,924	294	9,218
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	1,082	869	650	311	+	+	3,028	+	+	+
	Males	550	450	345	154	+	+	1,538	+	+	+
	Females	532	419	305	157	+	+	1,490	+	+	+
Hispanic <sup>d</sup>	Both Sexes	4,709	3,627	2,655	1,962	+	+	13,685	+	+	+
	Males	2,533	1,971	1,537	1,002	+	+	7,465	+	+	+
	Females	2,176	1,656	1,118	960	+	+	6,220	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)					Age-Adjusted <sup>f</sup>	
						30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.0404%	0.0007%	0.0102%	0.0396%	0.0664%	0.0697%	0.0524%	0.0423%	0.0421%	0.0328%	0.0402%
	Males	0.0430%	0.0011%	0.0112%	0.0395%	0.0644%	0.0732%	0.0593%	0.0520%	0.0505%	0.0387%	0.0427%
	Females	0.0379%	0.0003%	0.0092%	0.0397%	0.0683%	0.0662%	0.0458%	0.0336%	0.0352%	0.0292%	0.0379%
White <sup>c</sup>	Both Sexes	0.0461%	0.0006%	0.0111%	0.0452%	0.0764%	0.0801%	0.0588%	0.0480%	0.0477%	0.0377%	0.0458%
	Males	0.0488%	0.0009%	0.0122%	0.0446%	0.0733%	0.0829%	0.0658%	0.0587%	0.0570%	0.0437%	0.0482%
	Females	0.0434%	0.0003%	0.0100%	0.0457%	0.0797%	0.0773%	0.0518%	0.0380%	0.0400%	0.0340%	0.0437%
Black <sup>c</sup>	Both Sexes	0.0363%	0.0009%	0.0101%	0.0313%	0.0619%	0.0688%	0.0549%	0.0374%	0.0357%	0.0207%	0.0375%
	Males	0.0379%	0.0016%	0.0100%	0.0294%	0.0610%	0.0740%	0.0650%	0.0428%	0.0418%	0.0315%	0.0400%
	Females	0.0348%	-	0.0101%	0.0332%	0.0626%	0.0643%	0.0460%	0.0331%	0.0315%	0.0153%	0.0354%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0157%	0.0008%	0.0056%	0.0213%	0.0273%	0.0223%	0.0157%	0.0121%	0.0148%	0.0088%	0.0150%
	Males	0.0167%	0.0016%	0.0068%	0.0251%	0.0256%	0.0228%	0.0163%	0.0128%	0.0195%	0.0139%	0.0162%
	Females	0.0148%	-	0.0043%	0.0175%	0.0289%	0.0218%	0.0151%	0.0116%	0.0111%	0.0057%	0.0140%
Hispanic <sup>d</sup>	Both Sexes	0.0254%	0.0008%	0.0098%	0.0293%	0.0398%	0.0387%	0.0360%	0.0372%	0.0481%	0.0313%	0.0280%
	Males	0.0274%	0.0012%	0.0118%	0.0311%	0.0385%	0.0418%	0.0417%	0.0447%	0.0550%	0.0452%	0.0309%
	Females	0.0234%	-	0.0077%	0.0274%	0.0411%	0.0355%	0.0305%	0.0307%	0.0429%	0.0229%	0.0255%

<sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry

(d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.

<sup>e</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.

<sup>f</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

<sup>g h i</sup> (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 10.15  
Kaposi SarcomaEstimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	7,712	6,496	4,744	6,724	2,381	793	27,686	29,172	+	+
	Males	7,119	6,056	4,495	6,572	2,241	793	26,112	27,520	+	+
	Females	593	440	249	152	140	0	1,574	1,652	+	+
White <sup>b</sup>	Both Sexes	4,729	4,618	3,370	5,399	1,954	680	19,762	21,002	+	+
	Males	4,344	4,302	3,166	5,305	1,848	680	18,657	19,831	+	+
	Females	385	316	204	94	106	0	1,105	1,171	+	+
Black <sup>b</sup>	Both Sexes	2,413	1,579	1,167	882	276	36	6,280	6,388	+	+
	Males	2,296	1,476	1,133	859	253	36	5,981	6,089	+	+
	Females	117	103	34	23	23	0	299	299	+	+
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	149	116	80	85	+	+	439	+	+	+
	Males	144	109	80	85	+	+	427	+	+	+
	Females	5	7	0	0	+	+	12	+	+	+
Hispanic <sup>d</sup>	Both Sexes	1,291	1,120	898	1,198	+	+	4,767	+	+	+
	Males	1,141	1,046	844	1,167	+	+	4,453	+	+	+
	Females	150	74	54	31	+	+	314	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)					Age-Adjusted <sup>f</sup>	
						30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.0093%	-	-	0.0012%	0.0061%	0.0171%	0.0239%	0.0146%	0.0112%	0.0187%	0.0087%
	Males	0.0179%	-	-	0.0023%	0.0119%	0.0337%	0.0479%	0.0297%	0.0212%	0.0351%	0.0172%
	Females	0.0009%	-	-	-	0.0002%	0.0007%	0.0009%	0.0009%	0.0030%	0.0088%	0.0008%
White <sup>c</sup>	Both Sexes	0.0092%	-	-	0.0006%	0.0046%	0.0156%	0.0247%	0.0152%	0.0119%	0.0205%	0.0084%
	Males	0.0176%	-	-	0.0012%	0.0088%	0.0300%	0.0489%	0.0304%	0.0220%	0.0385%	0.0164%
	Females	0.0010%	-	-	-	-	0.0007%	0.0007%	0.0009%	0.0034%	0.0096%	0.0008%
Black <sup>c</sup>	Both Sexes	0.0144%	-	-	0.0053%	0.0188%	0.0351%	0.0325%	0.0170%	0.0115%	0.0099%	0.0149%
	Males	0.0289%	-	-	0.0101%	0.0389%	0.0741%	0.0670%	0.0371%	0.0241%	0.0153%	0.0308%
	Females	0.0011%	-	-	-	-	-	0.0024%	-	-	0.0073%	0.0011%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0025%	-	-	-	0.0019%	0.0041%	0.0051%	0.0051%	0.0033%	0.0065%	0.0023%
	Males	0.0050%	-	-	-	0.0039%	0.0086%	0.0111%	0.0110%	0.0075%	0.0132%	0.0049%
	Females	0.0002%	-	-	-	-	-	-	-	-	-	0.0001%
Hispanic <sup>d</sup>	Both Sexes	0.0090%	-	-	0.0008%	0.0071%	0.0202%	0.0288%	0.0180%	0.0188%	0.0480%	0.0115%
	Males	0.0166%	-	-	0.0015%	0.0137%	0.0387%	0.0568%	0.0372%	0.0340%	0.0748%	0.0218%
	Females	0.0012%	-	-	-	-	0.0009%	0.0016%	-	0.0074%	0.0318%	0.0019%

<sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry

(d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.

<sup>e</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.

<sup>f</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

<sup>g h i</sup> (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 11.21  
Cancer of the Kidney And Renal Pelvis (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	197,821	126,608	67,299	37,412	21,766	11,368	447,255	471,919	11,306	483,225
	Males	125,208	75,912	39,763	21,548	12,159	6,033	272,663	285,670	6,388	292,058
	Females	72,613	50,696	27,536	15,864	9,607	5,335	174,592	186,249	4,918	191,167
White <sup>b</sup>	Both Sexes	163,535	106,871	57,965	32,287	19,325	10,092	376,623	398,532	12,630	411,162
	Males	104,181	64,299	34,432	19,114	10,944	5,501	231,177	243,040	5,555	248,595
	Females	59,354	42,572	23,533	13,173	8,381	4,591	145,446	155,492	7,075	162,567
Black <sup>b</sup>	Both Sexes	24,741	14,067	6,760	3,877	1,912	1,027	51,108	53,377	2,261	55,638
	Males	15,098	8,271	3,806	1,764	928	390	29,758	30,672	803	31,475
	Females	9,643	5,796	2,954	2,113	984	637	21,350	22,705	1,458	24,163
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	5,275	2,998	1,503	728	+	+	10,646	+	+	+
	Males	3,330	1,818	882	437	+	+	6,552	+	+	+
	Females	1,945	1,180	621	291	+	+	4,094	+	+	+
Hispanic <sup>d</sup>	Both Sexes	18,532	10,738	5,477	2,630	+	+	38,078	+	+	+
	Males	10,729	6,142	3,065	1,355	+	+	21,693	+	+	+
	Females	7,803	4,596	2,412	1,275	+	+	16,385	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)					Age-Adjusted <sup>f</sup>	
						30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.1223%	0.0072%	0.0104%	0.0083%	0.0166%	0.0640%	0.1678%	0.3487%	0.5828%	0.5742%	0.1139%
	Males	0.1520%	0.0065%	0.0094%	0.0073%	0.0184%	0.0796%	0.2155%	0.4712%	0.8136%	0.8496%	0.1532%
	Females	0.0934%	0.0079%	0.0114%	0.0093%	0.0147%	0.0485%	0.1221%	0.2381%	0.3939%	0.4082%	0.0817%
White <sup>c</sup>	Both Sexes	0.1353%	0.0072%	0.0110%	0.0092%	0.0179%	0.0677%	0.1771%	0.3657%	0.6203%	0.6071%	0.1204%
	Males	0.1675%	0.0064%	0.0105%	0.0083%	0.0191%	0.0834%	0.2242%	0.4881%	0.8600%	0.9021%	0.1608%
	Females	0.1032%	0.0080%	0.0115%	0.0103%	0.0166%	0.0515%	0.1303%	0.2512%	0.4186%	0.4268%	0.0865%
Black <sup>c</sup>	Both Sexes	0.1109%	0.0102%	0.0129%	0.0102%	0.0169%	0.0703%	0.1863%	0.4191%	0.6528%	0.5643%	0.1271%
	Males	0.1359%	0.0107%	0.0095%	0.0080%	0.0193%	0.0889%	0.2483%	0.5884%	0.9346%	0.8312%	0.1745%
	Females	0.0880%	0.0096%	0.0164%	0.0124%	0.0147%	0.0540%	0.1321%	0.2866%	0.4565%	0.4320%	0.0932%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0639%	0.0041%	0.0042%	0.0023%	0.0078%	0.0353%	0.0916%	0.1847%	0.2996%	0.3621%	0.0617%
	Males	0.0816%	0.0026%	0.0032%	0.0021%	0.0100%	0.0450%	0.1275%	0.2647%	0.4262%	0.5207%	0.0857%
	Females	0.0476%	0.0055%	0.0053%	0.0025%	0.0058%	0.0268%	0.0608%	0.1192%	0.2009%	0.2646%	0.0432%
Hispanic <sup>d</sup>	Both Sexes	0.0717%	0.0051%	0.0092%	0.0059%	0.0169%	0.0604%	0.1538%	0.3401%	0.5670%	0.5780%	0.1100%
	Males	0.0806%	0.0040%	0.0078%	0.0046%	0.0161%	0.0687%	0.1823%	0.4378%	0.7854%	0.7695%	0.1407%
	Females	0.0626%	0.0063%	0.0105%	0.0073%	0.0178%	0.0518%	0.1262%	0.2556%	0.4040%	0.4622%	0.0863%

<sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry

(d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.

<sup>e</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.

<sup>f</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

<sup>g h i</sup> (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 12.21  
Cancer of the Larynx (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases. Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	37,495	22,927	14,880	10,026	6,247	3,941	90,561	98,731	1,183	99,914
	Males	30,349	18,227	12,109	7,974	5,036	3,187	72,871	79,284	965	80,249
	Females	7,146	4,700	2,771	2,052	1,211	754	17,690	19,447	218	19,665
White <sup>b</sup>	Both Sexes	31,208	19,536	12,769	8,702	5,446	3,449	76,765	83,961	916	84,877
	Males	25,277	15,618	10,451	6,886	4,426	2,816	61,893	67,622	745	68,367
	Females	5,931	3,918	2,318	1,816	1,020	633	14,872	16,339	171	16,510
Black <sup>b</sup>	Both Sexes	5,068	2,805	1,701	1,081	653	416	11,235	11,994	84	12,078
	Males	4,022	2,133	1,311	884	520	329	8,822	9,381	72	9,453
	Females	1,046	672	390	197	133	87	2,413	2,613	12	2,625
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	657	341	284	152	+	+	1,469	+	+	+
	Males	548	283	241	137	+	+	1,238	+	+	+
	Females	109	58	43	15	+	+	231	+	+	+
Hispanic <sup>d</sup>	Both Sexes	2,385	1,248	876	536	+	+	5,168	+	+	+
	Males	2,084	1,057	724	428	+	+	4,409	+	+	+
	Females	301	191	152	108	+	+	759	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence	All Ages	0-9	10-19	20-29	Age Specific (Crude)						Age-Adjusted <sup>f</sup>	
					30-39	40-49	50-59	60-69	70-79	80+	All Ages	
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.0234%	-	-	0.0002%	0.0009%	0.0052%	0.0262%	0.0744%	0.1362%	0.1277%	0.0217%
	Males	0.0385%	-	-	0.0003%	0.0012%	0.0073%	0.0408%	0.1276%	0.2531%	0.2861%	0.0398%
	Females	0.0086%	-	-	0.0002%	0.0006%	0.0032%	0.0121%	0.0263%	0.0405%	0.0322%	0.0074%
White <sup>c</sup>	Both Sexes	0.0262%	-	-	0.0003%	0.0010%	0.0060%	0.0282%	0.0785%	0.1447%	0.1337%	0.0230%
	Males	0.0428%	-	-	0.0004%	0.0013%	0.0081%	0.0431%	0.1326%	0.2667%	0.2966%	0.0417%
	Females	0.0097%	-	-	-	0.0007%	0.0039%	0.0134%	0.0279%	0.0421%	0.0343%	0.0079%
Black <sup>c</sup>	Both Sexes	0.0242%	-	-	-	0.0010%	0.0051%	0.0343%	0.1052%	0.1931%	0.1500%	0.0289%
	Males	0.0397%	-	-	-	0.0015%	0.0074%	0.0533%	0.1890%	0.3764%	0.3805%	0.0562%
	Females	0.0099%	-	-	-	-	0.0030%	0.0176%	0.0396%	0.0654%	0.0358%	0.0104%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0092%	-	-	-	-	0.0013%	0.0085%	0.0287%	0.0519%	0.0764%	0.0090%
	Males	0.0162%	-	-	-	-	0.0023%	0.0165%	0.0529%	0.0980%	0.1744%	0.0178%
	Females	0.0028%	-	-	-	-	-	0.0016%	0.0090%	0.0160%	0.0162%	0.0025%
Hispanic <sup>d</sup>	Both Sexes	0.0097%	-	-	0.0004%	0.0009%	0.0040%	0.0153%	0.0481%	0.1111%	0.1239%	0.0169%
	Males	0.0164%	-	-	-	0.0012%	0.0061%	0.0248%	0.0887%	0.2310%	0.2875%	0.0342%
	Females	0.0029%	-	-	-	-	0.0018%	0.0060%	0.0129%	0.0216%	0.0250%	0.0042%

<sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry  
<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
<sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.  
<sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.  
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.  
+ Not available.

Table 13.29  
LeukemiaEstimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	151,081	93,834	55,871	34,351	21,156	13,225	352,781	381,780	5,948	387,728
	Males	88,049	53,792	31,508	19,012	11,686	7,181	202,071	217,434	2,555	219,989
	Females	63,032	40,042	24,363	15,339	9,470	6,044	150,710	164,346	3,393	167,739
White <sup>b</sup>	Both Sexes	131,277	82,606	49,750	30,644	18,979	11,838	310,105	336,400	4,978	341,378
	Males	76,923	47,386	28,084	16,939	10,706	6,519	178,246	192,374	1,776	194,150
	Females	54,354	35,220	21,666	13,705	8,273	5,319	131,859	144,026	3,202	147,228
Black <sup>b</sup>	Both Sexes	11,697	6,698	3,511	1,991	1,196	683	24,928	26,326	933	27,259
	Males	6,434	3,856	1,890	1,016	550	292	13,656	14,251	427	14,678
	Females	5,263	2,842	1,621	975	646	391	11,272	12,075	506	12,581
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	3,532	2,348	1,461	1,113	+	+	8,763	+	+	+
	Males	2,016	1,289	815	598	+	+	4,870	+	+	+
	Females	1,516	1,059	646	515	+	+	3,893	+	+	+
Hispanic <sup>d</sup>	Both Sexes	13,363	8,826	5,612	3,995	+	+	33,014	+	+	+
	Males	7,450	5,029	3,037	2,228	+	+	18,476	+	+	+
	Females	5,913	3,797	2,575	1,767	+	+	14,538	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence	All Ages	Age Specific (Crude)									Age-Adjusted <sup>f</sup>	
		0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages	
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.0975%	0.0319%	0.0623%	0.0523%	0.0326%	0.0497%	0.0941%	0.1980%	0.3525%	0.4479%	0.0938%
	Males	0.1136%	0.0329%	0.0680%	0.0578%	0.0365%	0.0579%	0.1155%	0.2532%	0.4631%	0.6214%	0.1162%
	Females	0.0819%	0.0309%	0.0564%	0.0465%	0.0285%	0.0415%	0.0735%	0.1481%	0.2619%	0.3433%	0.0753%
White <sup>c</sup>	Both Sexes	0.1127%	0.0360%	0.0708%	0.0600%	0.0367%	0.0527%	0.1031%	0.2203%	0.3978%	0.5066%	0.1050%
	Males	0.1307%	0.0364%	0.0771%	0.0653%	0.0414%	0.0607%	0.1261%	0.2806%	0.5184%	0.6998%	0.1292%
	Females	0.0948%	0.0356%	0.0642%	0.0544%	0.0318%	0.0444%	0.0803%	0.1639%	0.2965%	0.3886%	0.0845%
Black <sup>c</sup>	Both Sexes	0.0547%	0.0155%	0.0282%	0.0293%	0.0221%	0.0434%	0.0642%	0.1400%	0.2401%	0.2860%	0.0616%
	Males	0.0625%	0.0166%	0.0319%	0.0322%	0.0237%	0.0519%	0.0781%	0.1741%	0.3324%	0.4001%	0.0776%
	Females	0.0476%	0.0143%	0.0244%	0.0265%	0.0206%	0.0360%	0.0521%	0.1134%	0.1759%	0.2295%	0.0500%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0478%	0.0254%	0.0518%	0.0354%	0.0213%	0.0370%	0.0535%	0.0788%	0.1148%	0.1356%	0.0478%
	Males	0.0556%	0.0285%	0.0555%	0.0423%	0.0226%	0.0446%	0.0648%	0.0937%	0.1421%	0.2058%	0.0575%
	Females	0.0407%	0.0222%	0.0479%	0.0284%	0.0202%	0.0303%	0.0437%	0.0666%	0.0935%	0.0925%	0.0399%
Hispanic <sup>d</sup>	Both Sexes	0.0608%	0.0364%	0.0717%	0.0601%	0.0344%	0.0462%	0.0636%	0.1137%	0.1854%	0.2072%	0.0691%
	Males	0.0672%	0.0375%	0.0781%	0.0684%	0.0420%	0.0538%	0.0731%	0.1266%	0.2035%	0.2906%	0.0798%
	Females	0.0542%	0.0352%	0.0651%	0.0512%	0.0262%	0.0383%	0.0543%	0.1025%	0.1719%	0.1568%	0.0599%

<sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry

(d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.

<sup>e</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.

<sup>f</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

<sup>g h i</sup> (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.



Table 13.30  
Acute Lymphocytic Leukemia

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	17,937	14,284	11,945	10,606	8,696	6,700	61,761	78,275	3,562	81,837
	Males	9,674	8,187	6,578	5,857	4,673	3,627	34,012	42,662	1,823	44,485
	Females	8,263	6,097	5,367	4,749	4,023	3,073	27,749	35,613	1,739	37,352
White <sup>b</sup>	Both Sexes	15,053	12,021	10,395	9,230	7,614	5,914	52,826	67,715	+	+
	Males	8,045	6,797	5,742	5,031	4,189	3,234	28,969	36,835	+	+
	Females	7,008	5,224	4,653	4,199	3,425	2,680	23,857	30,880	+	+
Black <sup>b</sup>	Both Sexes	1,532	1,167	715	684	576	339	4,555	5,339	+	+
	Males	916	798	330	393	258	155	2,619	2,990	+	+
	Females	616	369	385	291	318	184	1,936	2,349	+	+
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	829	722	524	527	+	+	2,768	+	+	+
	Males	447	393	320	318	+	+	1,552	+	+	+
	Females	382	329	204	209	+	+	1,216	+	+	+
Hispanic <sup>d</sup>	Both Sexes	5,567	4,212	2,843	2,476	+	+	15,901	+	+	+
	Males	3,113	2,496	1,497	1,412	+	+	9,017	+	+	+
	Females	2,454	1,716	1,346	1,064	+	+	6,884	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted <sup>f</sup>
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.0198%	0.0270%	0.0527%	0.0380%	0.0107%	0.0065%	0.0049%	0.0057%	0.0046%	0.0028%	0.0204%
	Males	0.0224%	0.0276%	0.0571%	0.0432%	0.0133%	0.0074%	0.0059%	0.0055%	0.0054%	0.0039%	0.0226%
	Females	0.0172%	0.0263%	0.0480%	0.0326%	0.0080%	0.0057%	0.0040%	0.0059%	0.0039%	0.0021%	0.0183%
White <sup>c</sup>	Both Sexes	0.0225%	0.0310%	0.0606%	0.0450%	0.0134%	0.0070%	0.0054%	0.0062%	0.0048%	0.0024%	0.0236%
	Males	0.0252%	0.0312%	0.0654%	0.0503%	0.0165%	0.0079%	0.0062%	0.0059%	0.0062%	0.0026%	0.0258%
	Females	0.0198%	0.0307%	0.0555%	0.0394%	0.0101%	0.0060%	0.0045%	0.0064%	0.0036%	0.0023%	0.0213%
Black <sup>c</sup>	Both Sexes	0.0100%	0.0116%	0.0230%	0.0179%	0.0042%	0.0041%	0.0027%	0.0030%	-	-	0.0093%
	Males	0.0119%	0.0137%	0.0265%	0.0201%	0.0052%	0.0047%	0.0034%	-	-	-	0.0107%
	Females	0.0082%	0.0095%	0.0194%	0.0158%	0.0033%	0.0036%	0.0021%	0.0035%	-	-	0.0079%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0137%	0.0204%	0.0414%	0.0232%	0.0045%	0.0058%	0.0041%	0.0043%	0.0042%	0.0040%	0.0148%
	Males	0.0161%	0.0213%	0.0443%	0.0292%	0.0052%	0.0060%	0.0060%	0.0043%	-	0.0106%	0.0166%
	Females	0.0114%	0.0195%	0.0382%	0.0171%	0.0038%	0.0057%	0.0026%	0.0042%	0.0062%	-	0.0131%
Hispanic <sup>d</sup>	Both Sexes	0.0287%	0.0315%	0.0621%	0.0464%	0.0135%	0.0091%	0.0073%	0.0097%	0.0081%	-	0.0250%
	Males	0.0322%	0.0321%	0.0670%	0.0539%	0.0175%	0.0106%	0.0093%	0.0066%	0.0079%	-	0.0277%
	Females	0.0252%	0.0310%	0.0569%	0.0383%	0.0093%	0.0077%	0.0053%	0.0123%	0.0084%	-	0.0222%

- <sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry  
<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
<sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.  
<sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.  
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.  
+ Not available.

Table 14.21  
Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases. Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	47,284	11,629	4,189	1,463	758	553	65,252	66,219	552	66,771
	Males	34,345	8,130	2,654	843	439	230	46,399	46,820	75	46,895
	Females	12,939	3,499	1,535	620	319	323	18,853	19,399	477	19,876
White <sup>b</sup>	Both Sexes	35,191	8,513	2,977	1,074	575	443	48,271	49,049	574	49,623
	Males	25,746	6,049	1,856	588	340	154	34,567	34,881	356 <sup>i</sup>	35,237
	Females	9,445	2,464	1,121	486	235	289	13,704	14,168	218 <sup>i</sup>	14,386
Black <sup>b</sup>	Both Sexes	6,910	1,201	358	69	81	35	8,607	8,699	+	+
	Males	5,013	774	184	46	23	25	6,039	6,088	+	+
	Females	1,897	427	174	23	58	10	2,568	2,611	+	+
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	4,293	1,647	740	262	+	+	6,976	+	+	+
	Males	2,988	1,185	504	180	+	+	4,888	+	+	+
	Females	1,305	462	236	82	+	+	2,088	+	+	+
Hispanic <sup>d</sup>	Both Sexes	7,053	1,588	592	243	+	+	9,531	+	+	+
	Males	4,971	1,122	367	165	+	+	6,666	+	+	+
	Females	2,082	466	225	78	+	+	2,865	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)									Age-Adjusted <sup>f</sup>	
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.0226%	0.0029%	0.0029%	0.0014%	0.0019%	0.0069%	0.0368%	0.0871%	0.0881%	0.0642%	0.0200%
	Males	0.0322%	0.0033%	0.0030%	0.0016%	0.0020%	0.0094%	0.0576%	0.1377%	0.1242%	0.1030%	0.0298%
	Females	0.0133%	0.0024%	0.0028%	0.0013%	0.0017%	0.0044%	0.0168%	0.0414%	0.0585%	0.0409%	0.0116%
White <sup>c</sup>	Both Sexes	0.0195%	0.0031%	0.0031%	0.0015%	0.0018%	0.0053%	0.0319%	0.0743%	0.0660%	0.0456%	0.0165%
	Males	0.0277%	0.0034%	0.0031%	0.0017%	0.0019%	0.0069%	0.0490%	0.1173%	0.0924%	0.0732%	0.0241%
	Females	0.0113%	0.0029%	0.0031%	0.0013%	0.0016%	0.0037%	0.0149%	0.0340%	0.0437%	0.0288%	0.0095%
Black <sup>c</sup>	Both Sexes	0.0186%	0.0012%	0.0008%	0.0013%	0.0019%	0.0050%	0.0352%	0.1135%	0.0735%	0.0389%	0.0192%
	Males	0.0269%	0.0018%	-	0.0014%	0.0022%	0.0061%	0.0509%	0.1903%	0.1116%	0.0736%	0.0302%
	Females	0.0111%	-	-	0.0012%	0.0016%	0.0040%	0.0214%	0.0534%	0.0469%	0.0217%	0.0108%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0417%	0.0029%	0.0037%	0.0010%	0.0025%	0.0153%	0.0625%	0.1374%	0.2209%	0.1848%	0.0400%
	Males	0.0605%	0.0040%	0.0041%	-	0.0026%	0.0241%	0.1104%	0.2198%	0.3189%	0.2906%	0.0621%
	Females	0.0245%	0.0018%	0.0033%	-	0.0024%	0.0075%	0.0213%	0.0699%	0.1444%	0.1198%	0.0225%
Hispanic <sup>d</sup>	Both Sexes	0.0179%	0.0035%	0.0031%	0.0012%	0.0013%	0.0061%	0.0506%	0.1135%	0.1221%	0.0731%	0.0258%
	Males	0.0248%	0.0043%	0.0034%	0.0011%	0.0015%	0.0093%	0.0801%	0.1813%	0.1656%	0.1076%	0.0384%
	Females	0.0109%	0.0027%	0.0028%	0.0013%	0.0012%	0.0028%	0.0220%	0.0547%	0.0896%	0.0523%	0.0151%

<sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry  
<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
<sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.  
<sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.  
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.  
+ Not available.

Table 15.27  
Cancer of the Lung And Bronchus (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	309,108	107,103	50,607	26,967	13,888	7,161	505,358	520,203	7,025	527,228
	Males	141,514	45,597	21,029	11,278	5,838	2,791	224,209	230,475	4,065	234,540
	Females	167,594	61,506	29,578	15,689	8,050	4,370	281,149	289,728	2,960	292,688
White <sup>b</sup>	Both Sexes	259,910	92,970	44,345	23,505	12,283	6,477	430,931	444,151	2,609	446,760
	Males	118,138	39,082	18,006	9,539	5,076	2,495	188,938	194,407	1,214	195,621
	Females	141,772	53,888	26,339	13,966	7,207	3,982	241,993	249,744	1,395	251,139
Black <sup>b</sup>	Both Sexes	35,388	9,995	4,554	2,480	1,237	516	53,477	54,678	237	54,915
	Males	16,796	4,500	2,206	1,173	581	208	25,142	25,728	129	25,857
	Females	18,592	5,495	2,348	1,307	656	308	28,335	28,950	108	29,058
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	10,569	3,030	1,295	721	+	+	15,726	+	+	+
	Males	5,134	1,487	596	391	+	+	7,666	+	+	+
	Females	5,435	1,543	699	330	+	+	8,060	+	+	+
Hispanic <sup>d</sup>	Both Sexes	11,882	3,966	1,842	954	+	+	18,827	+	+	+
	Males	5,184	1,705	804	413	+	+	8,206	+	+	+
	Females	6,698	2,261	1,038	541	+	+	10,621	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)					Age-Adjusted <sup>f</sup>	
						30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.1331%	0.0002%	0.0004%	0.0018%	0.0061%	0.0249%	0.1183%	0.3659%	0.8570%	0.8995%	0.1263%
	Males	0.1203%	0.0002%	0.0004%	0.0018%	0.0054%	0.0222%	0.1036%	0.3589%	0.8528%	1.0290%	0.1276%
	Females	0.1456%	0.0002%	0.0004%	0.0019%	0.0068%	0.0277%	0.1324%	0.3723%	0.8604%	0.8215%	0.1264%
White <sup>c</sup>	Both Sexes	0.1448%	0.0002%	0.0005%	0.0021%	0.0063%	0.0250%	0.1160%	0.3691%	0.8984%	0.9392%	0.1302%
	Males	0.1271%	-	0.0004%	0.0019%	0.0054%	0.0219%	0.0996%	0.3489%	0.8652%	1.0401%	0.1275%
	Females	0.1624%	-	0.0005%	0.0023%	0.0072%	0.0281%	0.1323%	0.3880%	0.9264%	0.8776%	0.1336%
Black <sup>c</sup>	Both Sexes	0.1143%	-	-	0.0013%	0.0062%	0.0298%	0.1659%	0.4751%	0.8974%	0.7497%	0.1378%
	Males	0.1119%	-	-	0.0017%	0.0054%	0.0296%	0.1482%	0.5327%	1.0370%	1.0324%	0.1580%
	Females	0.1164%	-	-	-	0.0068%	0.0300%	0.1814%	0.4300%	0.8001%	0.6097%	0.1258%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0978%	-	-	0.0011%	0.0053%	0.0219%	0.0960%	0.2759%	0.6124%	0.7478%	0.0967%
	Males	0.0992%	-	-	0.0014%	0.0053%	0.0192%	0.0951%	0.3034%	0.6831%	0.9694%	0.1099%
	Females	0.0966%	-	-	-	0.0052%	0.0243%	0.0967%	0.2533%	0.5573%	0.6116%	0.0876%
Hispanic <sup>d</sup>	Both Sexes	0.0355%	-	-	0.0015%	0.0039%	0.0130%	0.0516%	0.1603%	0.4362%	0.4930%	0.0630%
	Males	0.0305%	-	-	0.0013%	0.0034%	0.0121%	0.0441%	0.1492%	0.4348%	0.5768%	0.0640%
	Females	0.0406%	-	-	0.0017%	0.0044%	0.0140%	0.0588%	0.1700%	0.4373%	0.4424%	0.0630%

- <sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry  
<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
<sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.  
<sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.  
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.  
+ Not available.

Table 16.21  
Melanoma of the Skin (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	343,875	257,876	184,816	131,072	89,775	65,069	991,036	1,134,329	35,022	1,169,351
	Males	191,228	134,241	92,210	64,014	41,715	26,941	516,144	574,347	11,325	585,672
	Females	152,647	123,635	92,606	67,058	48,060	38,128	474,892	559,982	23,697	583,679
White <sup>b</sup>	Both Sexes	329,212	250,378	179,100	126,231	86,538	62,186	955,667	1,093,382	33,039	1,126,421
	Males	183,879	130,843	89,365	61,621	40,470	25,854	499,082	555,147	10,801	565,948
	Females	145,333	119,535	89,735	64,610	46,068	36,332	456,585	538,235	22,238	560,473
Black <sup>b</sup>	Both Sexes	1,198	780	590	479	328	177	3,282	3,733	94	3,827
	Males	483	283	281	267	143	12	1,423	1,531	35	1,566
	Females	715	497	309	212	185	165	1,859	2,202	59	2,261
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	890	644	487	300	+	+	2,400	+	+	+
	Males	450	283	182	129	+	+	1,072	+	+	+
	Females	440	361	305	171	+	+	1,328	+	+	+
Hispanic <sup>d</sup>	Both Sexes	6,216	4,607	3,540	2,253	+	+	17,235	+	+	+
	Males	2,690	1,767	1,151	740	+	+	6,591	+	+	+
	Females	3,526	2,840	2,389	1,513	+	+	10,644	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)									Age-Adjusted <sup>f</sup>	
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.2466%	0.0004%	0.0030%	0.0265%	0.0994%	0.2160%	0.3871%	0.6221%	0.9034%	1.0842%	0.2301%
	Males	0.2634%	0.0002%	0.0028%	0.0174%	0.0686%	0.1714%	0.3751%	0.7454%	1.2573%	1.7219%	0.2677%
	Females	0.2304%	0.0006%	0.0031%	0.0361%	0.1304%	0.2603%	0.3987%	0.5107%	0.6137%	0.6999%	0.2059%
White <sup>c</sup>	Both Sexes	0.3240%	0.0004%	0.0036%	0.0350%	0.1328%	0.2827%	0.4928%	0.7824%	1.1262%	1.3243%	0.2912%
	Males	0.3432%	0.0003%	0.0034%	0.0229%	0.0891%	0.2187%	0.4694%	0.9225%	1.5461%	2.0950%	0.3317%
	Females	0.3049%	0.0006%	0.0039%	0.0480%	0.1789%	0.3490%	0.5159%	0.6513%	0.7730%	0.8534%	0.2663%
Black <sup>c</sup>	Both Sexes	0.0072%	-	-	-	0.0031%	0.0065%	0.0112%	0.0175%	0.0421%	0.0595%	0.0086%
	Males	0.0069%	-	-	-	0.0021%	0.0049%	0.0106%	0.0209%	0.0525%	0.0895%	0.0100%
	Females	0.0074%	-	-	-	0.0040%	0.0079%	0.0118%	0.0149%	0.0349%	0.0446%	0.0080%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0140%	0.0008%	0.0009%	0.0026%	0.0057%	0.0152%	0.0214%	0.0321%	0.0472%	0.0632%	0.0134%
	Males	0.0131%	-	-	0.0021%	0.0056%	0.0114%	0.0182%	0.0366%	0.0583%	0.0707%	0.0136%
	Females	0.0148%	-	-	0.0031%	0.0058%	0.0186%	0.0241%	0.0284%	0.0386%	0.0585%	0.0134%
Hispanic <sup>d</sup>	Both Sexes	0.0326%	0.0003%	0.0013%	0.0041%	0.0182%	0.0437%	0.0789%	0.1279%	0.1736%	0.2366%	0.0467%
	Males	0.0246%	-	0.0011%	0.0025%	0.0098%	0.0263%	0.0556%	0.1103%	0.1954%	0.3119%	0.0426%
	Females	0.0407%	-	0.0016%	0.0059%	0.0271%	0.0618%	0.1015%	0.1431%	0.1574%	0.1910%	0.0522%

- <sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry  
<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
<sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.  
<sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.  
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.  
+ Not available.

Table 17.13  
MesotheliomaEstimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	4,083	717	346	281	162	153	5,564	5,903	+	+
	Males	2,873	377	153	81	48	37	3,518	3,628	+	+
	Females	1,210	340	193	200	114	116	2,046	2,275	+	+
White <sup>b</sup>	Both Sexes	3,858	700	267	246	147	153	5,193	5,492	+	+
	Males	2,723	377	125	70	45	37	3,328	3,410	+	+
	Females	1,135	323	142	176	102	116	1,865	2,082	+	+
Black <sup>b</sup>	Both Sexes	134	12	47	24	12	0	229	265	+	+
	Males	73	1	24	12	0	0	109	133	+	+
	Females	61	11	23	12	12	0	120	132	+	+
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	52	7	17	4	+	+	81	+	+	+
	Males	38	0	10	4	+	+	53	+	+	+
Hispanic <sup>d</sup>	Both Sexes	282	70	42	26	+	+	419	+	+	+
	Males	196	17	25	21	+	+	259	+	+	+
	Females	86	53	17	5	+	+	160	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted <sup>f</sup>
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.0015%	-	-	-	0.0003%	0.0008%	0.0016%	0.0037%	0.0079%	0.0094%	0.0014%
	Males	0.0019%	-	-	-	-	0.0006%	0.0015%	0.0051%	0.0125%	0.0186%	0.0020%
	Females	0.0011%	-	-	-	0.0004%	0.0009%	0.0016%	0.0024%	0.0042%	0.0038%	0.0010%
White <sup>c</sup>	Both Sexes	0.0018%	-	-	-	0.0003%	0.0010%	0.0019%	0.0044%	0.0092%	0.0105%	0.0017%
	Males	0.0023%	-	-	-	-	0.0008%	0.0019%	0.0059%	0.0146%	0.0202%	0.0024%
	Females	0.0013%	-	-	-	0.0004%	0.0012%	0.0019%	0.0030%	0.0046%	0.0046%	0.0011%
Black <sup>c</sup>	Both Sexes	0.0005%	-	-	-	-	-	0.0008%	0.0012%	0.0036%	0.0057%	0.0006%
	Males	0.0005%	-	-	-	-	-	-	-	-	-	0.0008%
	Females	0.0005%	-	-	-	-	-	-	0.0044%	-	-	0.0006%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0005%	-	-	-	-	-	-	0.0011%	0.0026%	0.0050%	0.0005%
	Males	0.0007%	-	-	-	-	-	-	0.0024%	0.0038%	0.0132%	0.0008%
Hispanic <sup>d</sup>	Both Sexes	0.0008%	-	-	-	-	0.0007%	0.0021%	0.0033%	0.0055%	0.0080%	0.0012%
	Males	0.0010%	-	-	-	-	-	0.0022%	0.0052%	0.0090%	0.0178%	0.0019%
	Females	0.0006%	-	-	-	-	0.0008%	0.0019%	0.0017%	-	-	0.0008%

<sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry

<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
<sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.

<sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

(h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 18.21  
Myeloma (Invasive)Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases. Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>e</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>	
Race	Sex											
All Races <sup>b</sup>	Both Sexes	75,648	26,835	9,541	3,669	1,720	599	117,239	118,272	267	118,539	
	Males	42,231	14,340	5,108	2,061	995	332	64,628	65,186	97	65,283	
	Females	33,417	12,495	4,433	1,608	725	267	52,611	53,086	170	53,256	
White <sup>b</sup>	Both Sexes	56,591	20,554	7,528	2,907	1,340	452	88,814	89,550	0	89,550	
	Males	32,622	11,414	4,199	1,660	768	266	50,593	51,023	0 <sup>i</sup>	51,023	
	Females	23,969	9,140	3,329	1,247	572	186	38,221	38,527	0 <sup>i</sup>	38,527	
Black <sup>b</sup>	Both Sexes	15,605	5,196	1,693	592	286	111	23,324	23,560	+	+	
	Males	7,769	2,414	747	299	191	61	11,383	11,505	+	+	
	Females	7,836	2,782	946	293	95	50	11,941	12,055	+	+	
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	1,934	650	214	91	+	+	2,927	+	+	+	
	Males	1,040	307	104	45	+	+	1,509	+	+	+	
	Females	894	343	110	46	+	+	1,418	+	+	+	
Hispanic <sup>d</sup>	Both Sexes	5,519	1,700	842	270	+	+	8,382	+	+	+	
	Males	3,117	954	449	177	+	+	4,728	+	+	+	
	Females	2,402	746	393	93	+	+	3,654	+	+	+	

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)						Age-Adjusted <sup>f</sup>
						30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race	Sex											
All Races <sup>c</sup>	Both Sexes	0.0323%	-	-	0.0003%	0.0025%	0.0131%	0.0403%	0.1000%	0.1719%	0.1637%	0.0300%
	Males	0.0362%	-	-	0.0004%	0.0029%	0.0158%	0.0459%	0.1161%	0.2179%	0.2226%	0.0370%
	Females	0.0284%	-	-	0.0003%	0.0020%	0.0104%	0.0350%	0.0854%	0.1343%	0.1282%	0.0243%
White <sup>c</sup>	Both Sexes	0.0320%	-	-	0.0004%	0.0023%	0.0117%	0.0369%	0.0931%	0.1649%	0.1597%	0.0283%
	Males	0.0369%	-	-	0.0005%	0.0029%	0.0142%	0.0435%	0.1114%	0.2102%	0.2251%	0.0357%
	Females	0.0271%	-	-	0.0003%	0.0017%	0.0091%	0.0304%	0.0759%	0.1268%	0.1197%	0.0222%
Black <sup>c</sup>	Both Sexes	0.0511%	-	-	-	0.0046%	0.0301%	0.0825%	0.2100%	0.3318%	0.3060%	0.0600%
	Males	0.0530%	-	-	-	0.0046%	0.0351%	0.0838%	0.2297%	0.4388%	0.4058%	0.0719%
	Females	0.0494%	-	-	-	0.0046%	0.0258%	0.0814%	0.1946%	0.2573%	0.2566%	0.0522%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0178%	-	-	-	0.0014%	0.0066%	0.0227%	0.0561%	0.0993%	0.1015%	0.0172%
	Males	0.0189%	-	-	-	0.0015%	0.0095%	0.0263%	0.0615%	0.1190%	0.1133%	0.0201%
	Females	0.0168%	-	-	-	0.0012%	0.0040%	0.0197%	0.0516%	0.0840%	0.0942%	0.0148%
Hispanic <sup>d</sup>	Both Sexes	0.0158%	-	-	0.0004%	0.0028%	0.0113%	0.0356%	0.0804%	0.1498%	0.1259%	0.0253%
	Males	0.0176%	-	-	-	0.0036%	0.0141%	0.0426%	0.0965%	0.1762%	0.1847%	0.0315%
	Females	0.0140%	-	-	-	0.0020%	0.0083%	0.0288%	0.0664%	0.1301%	0.0904%	0.0206%

<sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census. Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years.

<sup>b c d</sup> Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry

(d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.

<sup>e</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.

<sup>f</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

<sup>g h i</sup> (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 19.25  
Non-Hodgkin LymphomaEstimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases. Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>e</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>	
Race	Sex											
All Races <sup>b</sup>	Both Sexes	247,549	171,171	107,339	61,534	32,564	19,328	615,303	653,661	8,335	661,996	
	Males	134,164	89,969	55,681	31,794	16,734	10,167	325,886	346,187	4,460	350,647	
	Females	113,385	81,202	51,658	29,740	15,830	9,161	289,417	307,474	3,875	311,349	
White <sup>b</sup>	Both Sexes	213,854	150,511	94,695	54,077	29,075	17,504	537,797	572,570	8,781	581,351	
	Males	116,394	79,369	49,345	27,844	14,948	9,226	285,660	304,105	5,049	309,154	
	Females	97,460	71,142	45,350	26,233	14,127	8,278	252,137	268,465	3,732	272,197	
Black <sup>b</sup>	Both Sexes	20,241	13,137	8,292	4,757	2,078	1,220	48,274	50,604	724	51,328	
	Males	10,423	6,541	4,121	2,515	1,036	641	24,517	25,727	320	26,047	
	Females	9,818	6,596	4,171	2,242	1,042	579	23,757	24,877	404	25,281	
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	7,657	4,695	2,905	1,605	+	+	17,244	+	+	+	
	Males	4,140	2,454	1,466	835	+	+	9,081	+	+	+	
	Females	3,517	2,241	1,439	770	+	+	8,163	+	+	+	
Hispanic <sup>d</sup>	Both Sexes	19,630	11,818	7,221	3,986	+	+	43,564	+	+	+	
	Males	10,215	6,134	3,741	2,154	+	+	22,702	+	+	+	
	Females	9,415	5,684	3,480	1,832	+	+	20,862	+	+	+	

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)					Age-Adjusted <sup>f</sup>	
						30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race	Sex											
All Races <sup>c</sup>	Both Sexes	0.1698%	0.0032%	0.0126%	0.0269%	0.0493%	0.1043%	0.2167%	0.4262%	0.7404%	0.9295%	0.1595%
	Males	0.1825%	0.0039%	0.0175%	0.0329%	0.0570%	0.1217%	0.2481%	0.4839%	0.8492%	1.1279%	0.1858%
	Females	0.1574%	0.0025%	0.0074%	0.0206%	0.0415%	0.0871%	0.1865%	0.3741%	0.6513%	0.8100%	0.1374%
White <sup>c</sup>	Both Sexes	0.1923%	0.0031%	0.0130%	0.0286%	0.0505%	0.1109%	0.2320%	0.4639%	0.8169%	1.0158%	0.1727%
	Males	0.2057%	0.0040%	0.0184%	0.0350%	0.0582%	0.1300%	0.2640%	0.5217%	0.9297%	1.2247%	0.2001%
	Females	0.1790%	0.0023%	0.0073%	0.0217%	0.0423%	0.0912%	0.2002%	0.4098%	0.7220%	0.8882%	0.1491%
Black <sup>c</sup>	Both Sexes	0.1058%	0.0034%	0.0111%	0.0255%	0.0577%	0.1013%	0.1899%	0.3178%	0.4713%	0.4945%	0.1189%
	Males	0.1132%	0.0032%	0.0149%	0.0327%	0.0698%	0.1152%	0.2197%	0.3730%	0.5095%	0.5934%	0.1370%
	Females	0.0991%	0.0035%	0.0071%	0.0184%	0.0470%	0.0892%	0.1639%	0.2746%	0.4446%	0.4455%	0.1047%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.1024%	0.0032%	0.0118%	0.0200%	0.0339%	0.0655%	0.1367%	0.2558%	0.4282%	0.5914%	0.0989%
	Males	0.1117%	0.0040%	0.0151%	0.0235%	0.0375%	0.0734%	0.1587%	0.2924%	0.5153%	0.7550%	0.1176%
	Females	0.0938%	0.0025%	0.0083%	0.0164%	0.0305%	0.0584%	0.1177%	0.2260%	0.3602%	0.4909%	0.0844%
Hispanic <sup>d</sup>	Both Sexes	0.0820%	0.0023%	0.0107%	0.0209%	0.0354%	0.0800%	0.1682%	0.3344%	0.5519%	0.7044%	0.1220%
	Males	0.0843%	0.0023%	0.0145%	0.0254%	0.0407%	0.0913%	0.1829%	0.3652%	0.5875%	0.7970%	0.1347%
	Females	0.0797%	0.0023%	0.0067%	0.0160%	0.0297%	0.0682%	0.1540%	0.3077%	0.5254%	0.6484%	0.1112%

<sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census. Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years.

<sup>b c d</sup> Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry

(d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.

<sup>e</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.

<sup>f</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

<sup>g h i</sup> (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 20.27  
Cancer of the Oral Cavity and Pharynx (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases. Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>e</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>	
Race	Sex											
All Races <sup>b</sup>	Both Sexes	135,174	79,645	49,058	31,079	19,170	12,429	311,049	338,188	8,714	346,902	
	Males	94,793	54,023	32,240	19,170	11,779	7,070	210,257	225,397	4,836	230,233	
	Females	40,381	25,622	16,818	11,909	7,391	5,359	100,792	112,791	3,878	116,669	
White <sup>b</sup>	Both Sexes	117,625	69,563	42,874	27,002	16,731	10,924	271,118	294,815	7,531	302,346	
	Males	83,404	47,826	28,664	16,875	10,485	6,347	185,705	199,275	4,176	203,451	
	Females	34,221	21,737	14,210	10,127	6,246	4,577	85,413	95,540	3,355	98,895	
Black <sup>b</sup>	Both Sexes	10,089	5,087	3,510	2,048	1,279	891	21,817	23,750	401	24,151	
	Males	6,767	3,155	1,981	1,084	618	419	13,509	14,270	167	14,437	
	Females	3,322	1,932	1,529	964	661	472	8,308	9,480	234	9,714	
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	4,849	3,149	1,904	1,377	+	+	11,600	+	+	+	
	Males	3,067	1,891	1,113	799	+	+	7,065	+	+	+	
	Females	1,782	1,258	791	578	+	+	4,535	+	+	+	
Hispanic <sup>d</sup>	Both Sexes	7,369	4,040	2,303	1,547	+	+	15,651	+	+	+	
	Males	4,835	2,325	1,415	828	+	+	9,591	+	+	+	
	Females	2,534	1,715	888	719	+	+	6,060	+	+	+	

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)					Age-Adjusted <sup>f</sup>	
						30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race	Sex											
All Races <sup>c</sup>	Both Sexes	0.0857%	0.0004%	0.0025%	0.0067%	0.0172%	0.0497%	0.1439%	0.2721%	0.3339%	0.3226%	0.0776%
	Males	0.1165%	0.0004%	0.0024%	0.0066%	0.0167%	0.0612%	0.2101%	0.4154%	0.5009%	0.4783%	0.1119%
	Females	0.0557%	0.0005%	0.0027%	0.0068%	0.0178%	0.0382%	0.0805%	0.1427%	0.1972%	0.2288%	0.0485%
White <sup>c</sup>	Both Sexes	0.0951%	0.0005%	0.0024%	0.0065%	0.0166%	0.0484%	0.1517%	0.2936%	0.3652%	0.3478%	0.0823%
	Males	0.1307%	0.0004%	0.0021%	0.0064%	0.0154%	0.0613%	0.2233%	0.4489%	0.5464%	0.5198%	0.1195%
	Females	0.0597%	0.0006%	0.0027%	0.0065%	0.0179%	0.0350%	0.0807%	0.1483%	0.2128%	0.2428%	0.0498%
Black <sup>c</sup>	Both Sexes	0.0492%	-	0.0035%	0.0068%	0.0132%	0.0363%	0.1092%	0.1967%	0.2072%	0.1605%	0.0531%
	Males	0.0640%	-	0.0031%	0.0081%	0.0118%	0.0393%	0.1524%	0.3033%	0.3255%	0.2356%	0.0754%
	Females	0.0358%	-	0.0039%	0.0056%	0.0144%	0.0336%	0.0714%	0.1132%	0.1248%	0.1232%	0.0364%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0673%	-	0.0024%	0.0076%	0.0228%	0.0620%	0.1224%	0.1899%	0.2295%	0.2426%	0.0635%
	Males	0.0853%	-	0.0030%	0.0070%	0.0263%	0.0731%	0.1727%	0.2719%	0.3272%	0.3240%	0.0858%
	Females	0.0508%	-	0.0017%	0.0083%	0.0196%	0.0521%	0.0791%	0.1227%	0.1532%	0.1925%	0.0456%
Hispanic <sup>d</sup>	Both Sexes	0.0295%	0.0005%	0.0019%	0.0046%	0.0108%	0.0260%	0.0709%	0.1442%	0.1973%	0.1994%	0.0435%
	Males	0.0357%	-	0.0017%	0.0044%	0.0102%	0.0312%	0.0951%	0.1984%	0.2852%	0.2803%	0.0587%
	Females	0.0231%	-	0.0022%	0.0047%	0.0115%	0.0207%	0.0475%	0.0972%	0.1317%	0.1506%	0.0312%

- <sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.
- <sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry
- <sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.
- <sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.
- <sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.
- + Not available.



Table 21.15  
Cancer of the Ovary (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases. Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>e</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>										
All Races <sup>b</sup>	70,057	38,021	27,971	22,155	18,338	14,216	173,433	207,303	14,757	222,060
White <sup>b</sup>	60,367	32,857	24,544	19,599	16,416	12,771	150,987	181,274	12,476	193,750
Black <sup>b</sup>	5,474	2,614	1,678	1,368	1,148	979	12,095	14,446	1,518	15,964
Asian/Pacific Islander <sup>c</sup>	3,247	2,007	1,394	863	+	+	7,819	+	+	+
Hispanic <sup>d</sup>	7,171	3,477	2,312	1,679	+	+	15,172	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence and Race/Ethnicity

Age at Prevalence	Age Specific (Crude)										Age-Adjusted <sup>f</sup>
	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>											
All Races <sup>c</sup>	0.0988%	0.0004%	0.0061%	0.0196%	0.0351%	0.0799%	0.1725%	0.2680%	0.3131%	0.2519%	0.0865%
White <sup>c</sup>	0.1098%	0.0004%	0.0060%	0.0209%	0.0368%	0.0815%	0.1828%	0.2925%	0.3473%	0.2744%	0.0929%
Black <sup>c</sup>	0.0528%	-	0.0051%	0.0143%	0.0280%	0.0580%	0.0968%	0.1511%	0.1873%	0.1595%	0.0538%
Asian/Pacific Islander <sup>c</sup>	0.0853%	-	0.0068%	0.0187%	0.0332%	0.0885%	0.1787%	0.2188%	0.2099%	0.1659%	0.0757%
Hispanic <sup>d</sup>	0.0578%	-	0.0080%	0.0239%	0.0370%	0.0665%	0.1309%	0.2263%	0.2478%	0.2109%	0.0731%

<sup>a</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

<sup>b</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.

<sup>c</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years.

<sup>d</sup> Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry

(d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.

<sup>e</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.

<sup>f</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

<sup>g</sup> (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 22.21  
Cancer of the Pancreas (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases. Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>e</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>	
Race	Sex											
All Races <sup>b</sup>	Both Sexes	48,921	8,662	3,362	1,582	898	473	63,340	64,359	309	64,668	
	Males	24,740	4,361	1,485	638	315	160	31,505	31,846	140	31,986	
	Females	24,181	4,301	1,877	944	583	313	31,835	32,513	169	32,682	
White <sup>b</sup>	Both Sexes	40,732	7,235	2,847	1,192	675	335	52,645	53,392	256	53,648	
	Males	20,971	3,707	1,358	521	235	121	26,780	27,031	127	27,158	
	Females	19,761	3,528	1,489	671	440	214	25,865	26,361	129	26,490	
Black <sup>b</sup>	Both Sexes	5,815	949	344	191	139	94	7,393	7,589	130	7,719	
	Males	2,605	457	72	46	36	39	3,192	3,266	55	3,321	
	Females	3,210	492	272	145	103	55	4,201	4,323	75	4,398	
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	1,878	314	160	80	+	+	2,444	+	+	+	
	Males	884	144	60	23	+	+	1,114	+	+	+	
	Females	994	170	100	57	+	+	1,330	+	+	+	
Hispanic <sup>d</sup>	Both Sexes	3,508	655	238	143	+	+	4,593	+	+	+	
	Males	1,634	252	100	36	+	+	2,025	+	+	+	
	Females	1,874	403	138	107	+	+	2,568	+	+	+	

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)					Age-Adjusted <sup>f</sup>	
						30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race	Sex											
All Races <sup>c</sup>	Both Sexes	0.0178%	-	0.0002%	0.0010%	0.0024%	0.0082%	0.0243%	0.0516%	0.0924%	0.0855%	0.0165%
	Males	0.0178%	-	0.0002%	0.0004%	0.0022%	0.0081%	0.0246%	0.0571%	0.1045%	0.0971%	0.0180%
	Females	0.0178%	-	-	0.0016%	0.0027%	0.0082%	0.0239%	0.0466%	0.0825%	0.0786%	0.0155%
White <sup>c</sup>	Both Sexes	0.0189%	-	0.0002%	0.0010%	0.0023%	0.0079%	0.0238%	0.0523%	0.0953%	0.0858%	0.0167%
	Males	0.0192%	-	-	0.0004%	0.0020%	0.0079%	0.0244%	0.0587%	0.1096%	0.0992%	0.0184%
	Females	0.0185%	-	-	0.0015%	0.0027%	0.0080%	0.0233%	0.0463%	0.0833%	0.0776%	0.0153%
Black <sup>c</sup>	Both Sexes	0.0162%	-	-	0.0011%	0.0030%	0.0115%	0.0323%	0.0610%	0.0922%	0.0723%	0.0183%
	Males	0.0147%	-	-	-	0.0036%	0.0124%	0.0312%	0.0655%	0.0847%	0.0703%	0.0181%
	Females	0.0175%	-	-	0.0017%	0.0025%	0.0108%	0.0332%	0.0575%	0.0974%	0.0732%	0.0185%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0148%	-	-	0.0009%	0.0026%	0.0067%	0.0202%	0.0422%	0.0747%	0.0894%	0.0143%
	Males	0.0140%	-	-	-	0.0027%	0.0059%	0.0200%	0.0425%	0.0852%	0.0964%	0.0149%
	Females	0.0155%	-	-	0.0016%	0.0025%	0.0074%	0.0204%	0.0419%	0.0665%	0.0851%	0.0138%
Hispanic <sup>d</sup>	Both Sexes	0.0087%	-	-	0.0010%	0.0017%	0.0060%	0.0200%	0.0428%	0.0771%	0.0690%	0.0136%
	Males	0.0075%	-	-	-	0.0013%	0.0050%	0.0189%	0.0421%	0.0868%	0.0580%	0.0134%
	Females	0.0098%	-	-	0.0017%	0.0021%	0.0069%	0.0210%	0.0434%	0.0700%	0.0757%	0.0138%

<sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry  
<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
<sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.  
<sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.  
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.  
+ Not available.

Table 23.15  
Cancer of the Prostate (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases. Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>e</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>										
All Races <sup>b</sup>	1,038,106	913,894	640,540	333,354	133,996	19,597	3,050,359	3,084,477	732	3,085,209
White <sup>b</sup>	831,557	751,537	541,036	285,443	119,819	17,768	2,520,665	2,551,678	878	2,552,556
Black <sup>b</sup>	153,415	121,969	79,312	39,027	11,428	1,481	404,551	407,038	73	407,111
Asian/Pacific Islander <sup>c</sup>	22,429	18,438	11,325	4,631	+	+	57,828	+	+	+
Hispanic <sup>d</sup>	62,617	50,575	31,586	14,998	+	+	162,771	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence and Race/Ethnicity

Age at Prevalence	Age Specific (Crude)										Age-Adjusted <sup>f</sup>
	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>											
All Races <sup>c</sup>	1.6608%	-	0.0002%	0.0002%	0.0013%	0.0737%	1.0145%	4.9924%	12.5789%	16.4951%	1.7932%
White <sup>c</sup>	1.7681%	-	-	-	0.0011%	0.0644%	0.9596%	4.9247%	12.7390%	16.6536%	1.7953%
Black <sup>c</sup>	1.8660%	-	-	-	0.0034%	0.1951%	2.0595%	8.6530%	18.8869%	22.3298%	2.7793%
Asian/Pacific Islander <sup>c</sup>	0.7730%	-	-	-	-	0.0175%	0.3356%	2.0766%	6.1007%	10.1308%	0.8945%
Hispanic <sup>d</sup>	0.6046%	-	-	-	-	0.0398%	0.6047%	3.3682%	9.6657%	13.6355%	1.3650%

- <sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.
- <sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry
- <sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.
- <sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.
- <sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.
- + Not available.

Table 24.21  
Cancer of the Stomach (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	48,271	20,756	11,821	6,377	3,460	2,397	90,134	94,580	1,184	95,764
	Males	28,858	11,907	6,591	3,612	1,570	1,133	52,373	54,495	685	55,180
	Females	19,413	8,849	5,230	2,765	1,890	1,264	37,761	40,085	499	40,584
White <sup>b</sup>	Both Sexes	36,095	15,359	8,623	4,527	2,495	1,750	66,660	70,000	948	70,948
	Males	22,470	9,176	5,017	2,562	1,069	839	40,150	41,809	537	42,346
	Females	13,625	6,183	3,606	1,965	1,426	911	26,510	28,191	411	28,602
Black <sup>b</sup>	Both Sexes	7,404	3,232	1,948	1,062	430	368	14,039	14,623	170	14,793
	Males	3,783	1,521	959	551	239	149	7,053	7,305	98	7,403
	Females	3,621	1,711	989	511	191	219	6,986	7,318	72	7,390
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	4,065	2,127	1,205	742	+	+	8,345	+	+	+
	Males	2,241	1,216	628	429	+	+	4,636	+	+	+
	Females	1,824	911	577	313	+	+	3,709	+	+	+
Hispanic <sup>d</sup>	Both Sexes	6,915	2,863	1,585	896	+	+	12,452	+	+	+
	Males	3,639	1,508	834	430	+	+	6,487	+	+	+
	Females	3,276	1,355	751	466	+	+	5,965	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)					Age-Adjusted <sup>f</sup>	
						30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.0310%	-	0.0001%	0.0008%	0.0038%	0.0136%	0.0358%	0.0766%	0.1581%	0.2238%	0.0292%
	Males	0.0359%	-	-	0.0006%	0.0034%	0.0142%	0.0425%	0.0976%	0.2154%	0.3027%	0.0376%
	Females	0.0263%	-	0.0002%	0.0009%	0.0041%	0.0130%	0.0293%	0.0576%	0.1112%	0.1764%	0.0226%
White <sup>c</sup>	Both Sexes	0.0271%	-	0.0001%	0.0007%	0.0037%	0.0125%	0.0305%	0.0648%	0.1289%	0.1746%	0.0242%
	Males	0.0320%	-	-	0.0007%	0.0035%	0.0132%	0.0368%	0.0841%	0.1814%	0.2361%	0.0316%
	Females	0.0222%	-	-	0.0007%	0.0039%	0.0117%	0.0242%	0.0468%	0.0847%	0.1371%	0.0182%
Black <sup>c</sup>	Both Sexes	0.0306%	-	-	0.0007%	0.0037%	0.0155%	0.0497%	0.1055%	0.2012%	0.2594%	0.0370%
	Males	0.0324%	-	-	-	0.0034%	0.0166%	0.0549%	0.1282%	0.2632%	0.3242%	0.0455%
	Females	0.0289%	-	-	-	0.0040%	0.0146%	0.0451%	0.0876%	0.1580%	0.2273%	0.0312%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0525%	-	-	0.0010%	0.0040%	0.0176%	0.0524%	0.1209%	0.2930%	0.4956%	0.0519%
	Males	0.0605%	-	-	-	0.0031%	0.0178%	0.0654%	0.1551%	0.3846%	0.6833%	0.0674%
	Females	0.0452%	-	-	0.0015%	0.0049%	0.0174%	0.0413%	0.0928%	0.2215%	0.3802%	0.0407%
Hispanic <sup>d</sup>	Both Sexes	0.0235%	-	-	0.0006%	0.0053%	0.0180%	0.0462%	0.0988%	0.2081%	0.3122%	0.0390%
	Males	0.0242%	-	-	0.0007%	0.0048%	0.0189%	0.0486%	0.1155%	0.2743%	0.3588%	0.0463%
	Females	0.0229%	-	-	-	0.0058%	0.0171%	0.0438%	0.0843%	0.1588%	0.2840%	0.0337%

- <sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry  
<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
<sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.  
<sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.  
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.  
+ Not available.

Table 25.15  
Cancer of the Testis (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases. Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>e</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>										
All Races <sup>b</sup>	44,173	41,241	37,956	33,738	30,334	23,808	181,293	236,742	14,452	251,194
White <sup>b</sup>	40,424	38,554	35,621	31,909	29,120	23,069	169,734	223,234	13,836	237,070
Black <sup>b</sup>	1,416	1,048	1,034	776	434	301	4,603	5,476	143	5,619
Asian/Pacific Islander <sup>c</sup>	1,045	796	627	529	+	+	3,169	+	+	+
Hispanic <sup>d</sup>	7,120	5,618	4,172	3,004	+	+	20,855	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence and Race/Ethnicity

Age at Prevalence	Age Specific (Crude)										Age-Adjusted <sup>f</sup>
	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>											
All Races <sup>c</sup>	0.1029%	0.0024%	0.0067%	0.0729%	0.1797%	0.2245%	0.1790%	0.0873%	0.0359%	0.0204%	0.1021%
White <sup>c</sup>	0.1274%	0.0024%	0.0078%	0.0911%	0.2251%	0.2804%	0.2168%	0.1040%	0.0429%	0.0247%	0.1263%
Black <sup>c</sup>	0.0224%	0.0021%	0.0021%	0.0153%	0.0319%	0.0528%	0.0474%	0.0259%	-	-	0.0232%
Asian/Pacific Islander <sup>c</sup>	0.0346%	0.0032%	0.0052%	0.0311%	0.0573%	0.0649%	0.0575%	0.0287%	0.0104%	-	0.0331%
Hispanic <sup>d</sup>	0.0766%	0.0025%	0.0090%	0.0807%	0.1682%	0.1560%	0.1029%	0.0425%	0.0270%	-	0.0782%

<sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census. Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years.

<sup>b c d</sup> Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry

(d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.

<sup>e</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.

<sup>f</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

<sup>g h i</sup> (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 26.21  
Cancer of the Thyroid (Invasive)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	226,991	159,919	101,742	67,827	47,814	35,901	595,737	686,315	40,331	726,646
	Males	53,812	35,995	21,736	14,223	10,331	7,184	134,433	152,987	9,592	162,579
	Females	173,179	123,924	80,006	53,604	37,483	28,717	461,304	533,328	30,739	564,067
White <sup>b</sup>	Both Sexes	193,727	139,728	89,361	60,146	42,882	32,245	518,105	599,904	36,481	636,385
	Males	47,604	32,209	19,593	12,903	9,472	6,571	120,243	137,248	8,006	145,254
	Females	146,123	107,519	69,768	47,243	33,410	25,674	397,862	462,656	28,475	491,131
Black <sup>b</sup>	Both Sexes	16,106	9,857	5,930	3,350	2,297	1,568	37,190	41,208	1,731	42,939
	Males	2,673	1,795	1,066	596	478	283	6,527	7,188	207	7,395
	Females	13,433	8,062	4,864	2,754	1,819	1,285	30,663	34,020	1,524	35,544
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	11,618	7,327	4,766	3,068	+	+	27,710	+	+	+
	Males	2,340	1,306	838	483	+	+	5,129	+	+	+
Hispanic <sup>d</sup>	Both Sexes	9,278	6,021	3,928	2,585	+	+	22,581	+	+	+
	Males	24,208	15,450	9,560	5,966	+	+	57,122	+	+	+
Hispanic <sup>d</sup>	Males	4,379	2,540	1,628	940	+	+	9,798	+	+	+
	Females	19,829	12,910	7,932	5,026	+	+	47,324	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence	All Ages	0-9	10-19	20-29	Age Specific (Crude)						Age-Adjusted <sup>f</sup>	
					30-39	40-49	50-59	60-69	70-79	80+	All Ages	
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.1707%	0.0002%	0.0058%	0.0442%	0.1470%	0.2623%	0.3288%	0.3550%	0.3624%	0.2522%	0.1619%
	Males	0.0761%	0.0002%	0.0025%	0.0148%	0.0475%	0.1012%	0.1414%	0.1896%	0.2345%	0.1767%	0.0744%
	Females	0.2630%	0.0003%	0.0093%	0.0751%	0.2474%	0.4220%	0.5087%	0.5044%	0.4671%	0.2978%	0.2451%
White <sup>c</sup>	Both Sexes	0.1878%	0.0003%	0.0067%	0.0508%	0.1653%	0.2884%	0.3577%	0.3710%	0.3751%	0.2582%	0.1750%
	Males	0.0862%	0.0003%	0.0031%	0.0175%	0.0525%	0.1129%	0.1567%	0.2058%	0.2519%	0.1838%	0.0816%
	Females	0.2891%	0.0003%	0.0104%	0.0863%	0.2841%	0.4700%	0.5573%	0.5257%	0.4788%	0.3036%	0.2676%
Black <sup>c</sup>	Both Sexes	0.0845%	-	0.0012%	0.0145%	0.0616%	0.1385%	0.1715%	0.2392%	0.2691%	0.1728%	0.0911%
	Males	0.0305%	-	0.0037%	0.0145%	0.0450%	0.0632%	0.0990%	0.1449%	0.1333%	0.0370%	0.0370%
	Females	0.1338%	-	0.0019%	0.0250%	0.1032%	0.2205%	0.2662%	0.3490%	0.3555%	0.1924%	0.1359%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.1539%	-	0.0052%	0.0361%	0.1232%	0.2299%	0.2915%	0.3362%	0.3397%	0.2512%	0.1452%
	Males	0.0601%	-	0.0097%	0.0436%	0.0843%	0.1120%	0.1491%	0.1806%	0.1489%	0.0601%	0.0601%
Hispanic <sup>d</sup>	Both Sexes	0.2400%	-	0.0091%	0.0630%	0.1956%	0.3586%	0.4461%	0.4894%	0.4638%	0.3142%	0.2180%
	Males	0.1076%	-	0.0064%	0.0349%	0.1194%	0.1897%	0.2715%	0.3129%	0.3381%	0.2582%	0.1347%
	Females	0.0364%	-	0.0028%	0.0098%	0.0304%	0.0590%	0.0885%	0.1333%	0.1993%	0.1457%	0.0519%
		0.1800%	-	0.0101%	0.0622%	0.2142%	0.3256%	0.4488%	0.4684%	0.4417%	0.3261%	0.2137%

- <sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry  
<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
<sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.  
<sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.  
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.  
+ Not available.

Table 27.21  
Cancer of the Urinary Bladder (Invasive and *In Situ*)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 <sup>a</sup>	0 to <39 <sup>e</sup>	>=39 <sup>g</sup>	Complete <sup>h</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	258,861	166,885	108,338	67,631	41,018	24,547	636,212	686,873	9,567	696,440
	Males	198,805	126,147	79,502	49,160	29,960	18,109	478,980	514,985	6,216	521,201
	Females	60,056	40,738	28,836	18,471	11,058	6,438	157,232	171,888	3,351	175,239
White <sup>b</sup>	Both Sexes	235,842	153,987	100,993	63,682	38,820	23,349	587,040	635,235	7,501	642,736
	Males	182,132	116,764	74,310	46,360	28,293	17,165	443,444	477,600	4,764	482,364
	Females	53,710	37,223	26,683	17,322	10,527	6,184	143,596	157,635	2,737	160,372
Black <sup>b</sup>	Both Sexes	13,720	6,796	4,374	2,207	1,300	836	28,288	29,772	184	29,956
	Males	9,764	4,812	2,920	1,591	968	699	19,956	21,104	154	21,258
	Females	3,956	1,984	1,454	616	332	137	8,332	8,668	30	8,698
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	4,863	3,088	1,738	929	+	+	10,857	+	+	+
	Males	3,664	2,370	1,295	639	+	+	8,159	+	+	+
	Females	1,199	718	443	290	+	+	2,698	+	+	+
Hispanic <sup>d</sup>	Both Sexes	10,258	6,076	3,608	1,976	+	+	22,565	+	+	+
	Males	7,742	4,545	2,684	1,448	+	+	16,853	+	+	+
	Females	2,516	1,531	924	528	+	+	5,712	+	+	+

Estimated prevalence percent<sup>a</sup> on January 1, 2014, of the SEER<sup>c</sup> population diagnosed in the previous 22 years  
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)					Age-Adjusted <sup>f</sup>	
						30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races <sup>c</sup>	Both Sexes	0.1660%	0.0003%	0.0004%	0.0015%	0.0070%	0.0266%	0.1131%	0.3893%	0.9745%	1.6058%	0.1578%
	Males	0.2541%	0.0003%	0.0005%	0.0020%	0.0100%	0.0396%	0.1758%	0.6326%	1.6646%	3.1367%	0.2781%
	Females	0.0800%	0.0003%	0.0002%	0.0010%	0.0041%	0.0137%	0.0529%	0.1695%	0.4096%	0.6834%	0.0680%
White <sup>c</sup>	Both Sexes	0.2011%	0.0002%	0.0004%	0.0016%	0.0085%	0.0316%	0.1284%	0.4467%	1.1274%	1.7938%	0.1800%
	Males	0.3058%	-	0.0006%	0.0023%	0.0119%	0.0456%	0.1963%	0.7141%	1.9034%	3.5001%	0.3138%
	Females	0.0968%	0.0003%	-	0.0009%	0.0048%	0.0171%	0.0609%	0.1965%	0.4748%	0.7513%	0.0776%
Black <sup>c</sup>	Both Sexes	0.0658%	0.0007%	-	0.0010%	0.0033%	0.0157%	0.0737%	0.2193%	0.4881%	0.8304%	0.0845%
	Males	0.0983%	-	-	-	0.0049%	0.0265%	0.1185%	0.3746%	0.8409%	1.6414%	0.1518%
	Females	0.0363%	-	-	0.0015%	0.0019%	0.0063%	0.0345%	0.0978%	0.2424%	0.4285%	0.0411%
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	0.0701%	-	-	0.0009%	0.0025%	0.0097%	0.0494%	0.1593%	0.3824%	0.8381%	0.0696%
	Males	0.1091%	-	-	0.0013%	0.0028%	0.0157%	0.0820%	0.2701%	0.6789%	1.5600%	0.1244%
	Females	0.0343%	-	-	-	0.0022%	0.0044%	0.0213%	0.0686%	0.1511%	0.3945%	0.0303%
Hispanic <sup>d</sup>	Both Sexes	0.0425%	-	-	0.0010%	0.0039%	0.0148%	0.0539%	0.1761%	0.4806%	0.7966%	0.0775%
	Males	0.0628%	-	-	0.0013%	0.0054%	0.0199%	0.0830%	0.2776%	0.8656%	1.5520%	0.1384%
	Females	0.0220%	-	-	0.0007%	0.0023%	0.0096%	0.0258%	0.0881%	0.1933%	0.3400%	0.0341%

- <sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.  
<sup>b c d</sup> Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry  
<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
<sup>f</sup> Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.  
<sup>g h i</sup> Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.  
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.  
+ Not available.

Table 28.12  
Childhood Cancer (Invasive, <20 Years old at diagnosis)

Estimated United States Cancer Prevalence Counts<sup>a</sup> on January 1, 2014  
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <20 <sup>e</sup>	0 to <39 <sup>e</sup>	>=39 <sup>f</sup>	Complete <sup>g</sup>
<u>Race</u>	<u>Sex</u>										
All Races <sup>b</sup>	Both Sexes	67,020	57,552	52,926	46,382	41,337	34,624	257,299	348,784	+	+
	Males	34,757	30,607	27,359	24,340	21,530	17,107	134,466	179,038	+	+
	Females	32,263	26,945	25,567	22,042	19,807	17,517	122,833	169,746	+	+
White <sup>b</sup>	Both Sexes	53,438	47,186	44,572	38,930	35,007	30,212	212,382	292,628	+	+
	Males	27,742	25,277	23,108	20,327	18,424	14,965	111,340	150,746	+	+
	Females	25,696	21,909	21,464	18,603	16,583	15,247	101,042	141,882	+	+
Black <sup>b</sup>	Both Sexes	8,228	6,538	5,275	4,592	4,023	2,816	27,863	35,469	+	+
	Males	4,231	3,389	2,624	2,397	1,998	1,306	14,230	17,626	+	+
	Females	3,997	3,149	2,651	2,195	2,025	1,510	13,633	17,843	+	+
Asian/ Pacific Islander <sup>c</sup>	Both Sexes	3,051	2,401	1,946	1,794	+	+	9,192	+	+	+
	Males	1,583	1,228	1,057	969	+	+	4,837	+	+	+
	Females	1,468	1,173	889	825	+	+	4,355	+	+	+
Hispanic <sup>d</sup>	Both Sexes	14,399	11,549	9,164	7,346	+	+	45,036	+	+	+
	Males	7,592	6,476	4,965	3,820	+	+	24,307	+	+	+
	Females	6,807	5,073	4,199	3,526	+	+	20,729	+	+	+

<sup>a</sup> US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.

<sup>b c d</sup> Prevalence was calculated using the First Malignant Primary Only for a person.  
Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry

<sup>e</sup> (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.  
Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.

<sup>f g</sup> (f) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (g) Complete prevalence is obtained by summing 0 to <39 and >=39.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.



Table 29.7  
U.S. Childhood Cancer Survivors at January 1, 2014  
Number of People Previously Diagnosed with Cancer as Children (Ages 0-19 Years) in the United States and Alive January 1, 2014  
By International Classification of Childhood Cancer (ICCC)<sup>a</sup> Selected Group and Subgroup, Age Group, and Sex

Site	Sex	Complete Prevalence Counts by Age at Prevalence							All Ages		
		0-19	20-29	30-39	40-49	50-59	60+	All Ages	Diagnosed between 1975-2013	Diagnosed before 1975	% <sup>b</sup>
									Count	Count	
All Sites	Both	117,572	103,558	70,818	56,108	45,829	25,461	419,346	348,520	70,826	17
	Male	62,560	54,527	35,264	25,960	19,059	12,162	209,532	179,151	30,381	14
	Female <sup>c</sup>	55,012	49,031	35,554	30,148	26,770	13,299	209,814	169,369	40,445	19
I Leukemia	Both	37,029	23,282	13,980	7,126	2,678	487	84,582	80,028	4,554	5
	Male	20,271	12,628	7,085	3,640	1,257	206	45,087	43,121	1,966	4
	Female	16,758	10,654	6,895	3,486	1,421	281	39,495	36,907	2,588	7
Acute lymphocytic leukemia <sup>d</sup>	Both	31,024	19,100	11,726	6,347	1,433	38	69,668	66,335	3,333	5
	Male	16,816	10,542	6,044	3,447	800	21	37,670	35,955	1,715	5
	Female	14,208	8,558	5,682	2,900	633	17	31,998	30,380	1,618	5
I(b) Acute myeloid leukemia	Both	4,327	2,918	1,349	1,024	900	622	11,140	9,352	1,788	16
	Male	2,305	1,417	589	462	439	326	5,538	4,665	873	16
	Female	2,022	1,501	760	562	461	296	5,602	4,687	915	16
II(a) Hodgkin lymphoma	Both	4,737	9,479	8,166	7,675	5,983	2,305	38,345	33,108	5,237	14
	Male	2,525	5,045	3,920	3,982	2,884	1,189	19,545	16,765	2,780	14
	Female	2,212	4,434	4,246	3,693	3,099	1,116	18,800	16,343	2,457	13
II(b,c,e) Non-Hodgkin lymphoma	Both	7,021	8,051	5,152	3,627	2,187	1,694	27,732	24,083	3,649	13
	Male	4,910	5,212	3,487	2,405	1,142	969	18,125	16,150	1,975	11
	Female	2,111	2,839	1,665	1,222	1,045	725	9,607	7,933	1,674	17
III CNS and misc intracranial & intraspinal neoplasms	Both	21,595	16,114	10,255	8,405	6,353	2,709	65,431	54,568	10,863	17
	Male	11,466	8,866	5,666	4,196	2,926	1,217	34,337	29,386	4,951	14
	Female	10,129	7,248	4,589	4,209	3,427	1,492	31,094	25,182	5,912	19
IV Neuroblastoma & other peripheral nervous cell tumor	Both	9,904	4,373	2,740	1,815	1,731	1,272	21,835	17,429	4,406	20
	Male	4,927	2,328	1,308	643	604	280	10,090	8,726	1,364	14
	Female	4,977	2,045	1,432	1,172	1,127	992	11,745	8,703	3,042	26
VI Renal tumors	Both	7,618	5,146	3,937	4,403	3,447	1,488	26,039	17,533	8,506	33
	Male	3,634	2,468	1,746	2,454	1,868	873	13,043	8,195	4,848	37
	Female	3,984	2,678	2,191	1,949	1,579	615	12,996	9,338	3,658	28
VIII Malignant bone tumors	Both	3,856	4,635	3,441	2,576	2,607	1,484	18,599	15,029	3,570	19
	Male	2,266	2,662	1,925	1,366	1,139	758	10,116	8,469	1,647	16
	Female	1,590	1,973	1,516	1,210	1,468	726	8,483	6,560	1,923	23
VIII(a) Osteosarcoma	Both	2,048	2,585	1,772	1,440	1,323	1,077	10,245	8,163	2,082	20
	Male	1,144	1,396	1,022	762	574	509	5,407	4,464	943	17
	Female	904	1,189	750	678	749	568	4,838	3,699	1,139	24
VIII(c) Ewing tumor & related sarcomas of bone	Both	1,487	1,482	1,115	692	450	258	5,484	4,876	608	11
	Male	902	901	564	321	193	102	2,983	2,761	222	7
	Female	585	581	551	371	257	156	2,501	2,115	386	15
IX Soft tissue & other extraosseous sarcomas	Both	7,192	7,049	4,903	4,621	5,041	6,240	35,046	23,759	11,287	32
	Male	3,948	3,773	2,527	2,339	2,432	3,514	18,533	12,577	5,956	32
	Female	3,244	3,276	2,376	2,282	2,609	2,726	16,513	11,182	5,331	32
X Germ cell & trophoblastic tumors & neoplasms of gonads	Both	5,236	8,494	5,893	6,021	7,021	8,755	41,420	26,988	14,432	35
	Male	2,669	5,564	3,643	3,254	3,442	3,897	22,469	15,983	6,486	29
	Female	2,567	2,930	2,250	2,767	3,579	4,858	18,951	11,005	7,946	42

<sup>a</sup> International Classification of Childhood Cancer is based on ICD-O-3. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. Cancer. April 1, 2005; Vol 103, No. 7, pg 1457-1467.  
<sup>b</sup> Percent diagnosed before 1975 of all ages complete prevalence counts.  
<sup>c</sup> All sites females excludes breast cancer.  
<sup>d</sup> SEER site recode Acute Lymphocytic Leukemia was used instead of the ICCC classification lymphocytic leukemia (Ia) because of statistical modeling requirements.  
For more information regarding the modeling of the prevalence estimates, see Mariotto et al. Long-Term Survivors of Childhood Cancers in the United States. Cancer Epidemiol Biomarkers Prev 2009, page 1034.